Skip to content
School of Pharmacy

team: Pharmacy Faculty

/department-of-pharmacy/faculty-staff/faculty/

Zach Marcum

Education

  • Doctor of Pharmacy (PharmD), Butler University
  • Doctor of Philosophy (PhD), Clinical & Translational Science, University of Pittsburgh School of Medicine
  • Master of Science (MS), Clinical Research, University of Pittsburgh

Jeffrey Jarvik

Biography

Dr. Jeffrey G. Jarvik, MD, MPH, is a Professor of Radiology and Neurological Surgery (joint) at the University of Washington, and an adjunct professor in the Departments of Pharmacy and Orthopedics & Sports Medicine. He is also a radiologist at UW Medical Center, specializing in neuroradiology. Dr. Jarvik serves as the Principal Investigator and Director of the NIH/NIAMS-funded UW Clinical Learning Evidence And Research (CLEAR) Center for Musculoskeletal Disorders. In addition, he is Co‑Director of both the Comparative Effectiveness, Cost and Outcomes Research Center (CECORC) and the Health Services Research Section within the Department of Radiology.

An internationally recognized expert in MR imaging of the spine, Dr. Jarvik is also a leader in health services and comparative effectiveness research as it relates to radiology. He earned his medical degree from the University of California, San Diego, and his Master of Public Health from the University of Washington. He completed his residency in diagnostic radiology and fellowship in neuroradiology at the Hospital of the University of Pennsylvania, along with completing the Robert Wood Johnson Clinical Scholars program.

Dr. Jarvik’s clinical and research interests include the imaging and treatment of patients with low back pain, osteoporotic fractures, comparative effectiveness research, pragmatic clinical trials, and health services research.

Education

  • Master of Public Health, School of Public Health & Community Medicine, University of Washington
  • Doctor of Medicine (MD), University of San Diego School of Medicine
  • Fellowship in Neuroradiology, Hospital of the University of Pennsylvania
  • Residency in Diagnostic Radiology, Hospital of the University of Pennsylvania

Jan Hansen

Education

  • Doctor of Philosophy (PhD), Pharmacy Administration and Pharmacy Policy, University of South Carolina
  • Bachelor of Science, Pharmacy, University of Iowa

Ruth Etzioni

Affiliations

  • Professor, Biostatistics Program, Public Health Sciences Division, Fred Hutch
  • Member, Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch
  • Rosalie and Harold Rea Brown Endowed Chair, Fred Hutch
  • Affiliate Investigator, Clinical Research Division, Fred Hutch

Biography

Dr. Ruth Etzioni is a biostatistician who primarily focuses on cancer screening and early detection. Much of her work is in the area of prostate and breast cancer, where she develops methods for evaluating diagnostic tests; creates mathematical models to reflect the impact of screening tests on the incidence and mortality rates of these cancers; calculates costs and benefits of preventive screening; tracks population trends with regard to screening and related behaviors and works with investigators on trial design and analysis. Dr. Etzioni also researches overdiagnoses associated with certain screening tests — when screening finds cancers that would not cause symptoms or death within a patient’s natural lifetime. She also evaluates novel cancer biomarkers and tracks patterns and outcomes of cancer care. Dr. Etzioni leads the biostatistics core for the National Cancer Institute-funded multicenter Northwest Prostate Cancer Specialized Program of Research Excellence, or SPORE, and she has a longstanding interest in researching, tracking and working to eliminate health disparities.

Education

  • PhD, Carnegie Mellon University, Statistics
  • MS, Carnegie Mellon University, Statistics
  • BS, University of Cape Town, Statistics

Research Interests

Development and implementation of statistical methods for prostate cancer studies

Deb Atherly

Education

  • Doctor Of Philosophy in Pharmaceutical Sciences, University of Washington
  • Master of Public Health, Health Services, University of Washington
  • Bachelor of Science in Pharmacy, University of Washington

Tony Yang

 

 

Biography

Tony Yang is a part-time lecturer in the University of Washington (UW) Department of Pharmacy and contributes to the UW BRAMS Practicum Program. He began his career in biopharmaceutical sector, specializing in quality assurance (QA). In this role, he supported quality management systems (QMS) and led cleanroom environmental monitoring initiatives. Tony later transitioned to the in vitro diagnostics (IVD) sector, where he continued advancing QMS practices and managed regulatory submissions, including 510(k) clearances and EU Technical Files. His expertise expanded into regulatory affairs (RA), guiding medical device compliance during the COVID-19 enforcement policy period. Currently, Tony serves as a Senior Regulatory Coordinator at Fred Hutchinson Cancer Center in Seattle, focusing on Research IND management and providing regulatory guidance to physicians and study teams. Yang is a graduate of the UW BRAMS program.

Amanda Olson

 

Biography

Amanda Olson is an affiliate assistant professor in the UW’s School of Pharmacy, where she co-teaches the Technical Writing courses. She brings ten years of experience in oncology medical writing, with a primary focus on regulatory submissions, clinical study documentation, and plain language communication. In her industry role, Olson serves as a senior manager leading content strategy and development, supporting cross functional teams, and mentoring early career writers. Olson values and strives for audience aware writing, clear structure, and collaborative processes that help teams translate complex data into concise, actionable documents for regulators, clinicians, and patients. Olson is a graduate of the UW BRAMS program.

Laurie Mendelson

 

 

Courses taught

  • PHARM 516: Introduction to Biomedical Regulatory Affairs
  • PHARM 517: Introduction to Biomedical Regulatory Affairs
  • PHARM 518: Product Testing, Evaluation & Post-Market Issues

Biography

Laurie Mendelson is an affiliate assistant professor in the UW Department of Pharmacy, where she co-teaches the courses for the Certificate in Biomedical Regulatory Affairs. She is the former director of the Division of Health Communication at FDA’s Center for Devices and Radiological Health. After leaving the FDA, Mendelson joined Bigfoot Biomedical, where she helped the company gain its first FDA 510(k) clearances (premarket submissions for regulatory approval) and implement post-market surveillance for a novel diabetes product. Currently, Mendelson consults with several medical device companies, providing guidance and hands-on support for pre- and post-market FDA regulatory compliance. She has a special interest in mentoring early-stage start-ups that are just beginning their regulatory journeys. Mendelson has a master’s degree in biomedical engineering from Case Western Reserve University.

Alexander Cutler

 

 

Courses taught

  • PHRMRA 536 Skills for the Regulatory Affairs Professional
  • PHARM 516: Introduction to Biomedical Regulatory Affairs
  • PHARM 517: Introduction to Biomedical Regulatory Affairs
  • PHARM 518: Product Testing, Evaluation & Post-Market Issues

Biography

Alexander N. Cutler is an affiliate assistant professor in the UW’s School of Pharmacy, where he teaches the Regulatory Skills course and the year-long Regulatory Affairs sequence. He brings over a decade of consulting experience as principal of Cutler Consulting, with a primary focus on medical devices containing software, software as a medical device (SaMD) and combination products. Cutler has also advised on pharmaceuticals, biologics, dietary supplements and cosmetics. Cutler’s clientele increasingly includes companies developing artificial intelligence for use in regulated industries. He has served in executive leadership and advisory board roles throughout the industry. Cutler earned his bachelor’s degree in biochemistry from Western Washington University and his master’s degree from the UW BRAMS program.

Mohammad Shawish

 

 

Courses taught

  • PHARM 516: Introduction to Biomedical Regulatory Affairs
  • PHARM 517: Introduction to Biomedical Regulatory Affairs
  • PHARM 518: Product Testing, Evaluation & Post-Market Issues

Biography

Mohammad Shawish is an affiliate assistant professor in the UW Department of Pharmacy. He is an accomplished medical affairs professional in the pharmaceutical industry, currently working at Jazz Pharmaceuticals as a senior medical science liaison in the epilepsy division. Throughout his career, Shawish has been instrumental in supporting product launches, conducting medical education initiatives and fostering strong relationships with the medical community. His contributions have significantly impacted the successful implementation of medical strategies and the advancement of patient care. He has demonstrated success in supporting product launches and overseeing products throughout their life cycle. Shawish is a pharmacist by training, and holds a doctorate in pharmacy from the Massachusetts College of Pharmacy and Health Sciences. He’s also a graduate of the UW BRAMS program.

Andreea Tofan

Education

  • BSc in Pharm, University of British Columbia
  • PharmD, University of Washington

Courses Taught

  • PHRMCY 544, 545, 546, 547 Pharmacy Provider Series in 2nd & 3rd year
  • PHARM 598 Serminar in Current Pharmacy Practice Topics

Biography

Andreea Tofan received her BSc in Pharmacy at the University of British Columbia and her PharmD at the University of Washington. She completed a PGY1 residency at Deaconess Medical Center in Spokane and is a Board Certified Pharmacotherapy Specialist. Her practice experience is in Internal Medicine in various inpatient settings in Canada and the US.

Joshua Villarreal

Joshua Villarreal received his PharmD degree from the University of Arizona and a Masters in Public Administration degree from the University of Washington.  Joshua completed his PGY1 Residency at the Hospital of the University of Pennsylvania and has pursued a variety of interests in pharmacy practice including inpatient care as a general medicine pharmacist, ambulatory care in cardiology, administrative and community care as a Tribal Medicine specialist with the Muckleshoot Indian Tribe, and critical care as an emergency medicine pharmacist at the University of Washington Medical Center. Joshua is currently in a combined role with the University of Washington Medicine’s Department of Pharmacy and the School of Pharmacy as Lead Clinical Educator to coordinate the efforts of pharmacy preceptors and faculty in developing our students’ brilliance.

Selected Publications

Coler, C., Patel, K., Balatico, A. J., Ro, K., Villarreal, J., Coronado, N., & Williams, E. (2025). Doctor for a day: the impact of a health professions enrichment program on self-efficacy. Frontiers in medicine, 12, 1511405. Doi: 10.3389/fmed.2025.1511405 Ro K, Villarreal J. A BOLD Framework to Support Diverse Faculty. Nurse Educ. Published online March 13, 2024. doi:10.1097/NNE.0000000000001638

Jessica Urban

Course taught

  • PHRMRA 528 Medical Risk Analysis & Management
  • PHRMRA 548 Practicum

Biography

Jessica Urban is an affiliate assistant professor in the Department of Pharmacy. She is a consultant with more than 25 years of experience in the product development of medical devices and drug/device combinations in Quality, Engineering, Program Management and Business Development roles. She’s served on the UW Institute of Translational Health Sciences Drug & Device Advisory Committee since 2018 and has been a New Ventures Mentor at UW’s CoMotion since 2016, guiding early-stage innovators on regulatory, product development and business development strategy. Urban earned her bachelor’s degree in mechanical engineering at Northern Arizona University, master’s degree in medical engineering at the University of Washington and a certificate from the UW Foster School of Business Executive Development Program.

Brent Lewis

Course taught

  • PHRMRA 536 Skills for the Regulatory Affairs Professional

Biography

Brent Lewis is an affiliate assistant professor in the Department of Pharmacy. He began his career in biotechnology, establishing and overseeing the quality control labs for biotechnology products where he wrote the chemistry, manufacturing and control (CMC) sections of several investigational new drug (IND) applications. Lewis went on to become a vice president of quality and regulatory affairs at several global medical device companies where he managed complex 510k submissions; led routine and for-cause FDA inspections; resolved FDA warning letters; oversaw mergers, acquisitions and integrations; and established quality systems for various companies. Today, as an IT leader responsible for quality, regulatory, R&D and commercial IT solutions at a global medical device company, he’s at the intersection of quality, regulatory and business operations, and focused on solutions to harmonize them. He has a bachelor’s degree in biology from Seattle University.

Sonal Jain

 

Courses taught

  • PHRMRA 525: Implementation & Conduct of Clinical Trials
  • PHRMRA 526: Project Management & the Business of Clinical Trials
  • PHRMRA 548: Practicum
  • PHRMRA 554: Advanced Medical Products Regulation I

Biography

Sonal Jain is a lecturer in the Department of Pharmacy and assists with the Clinical Trials Certificate and Regulatory Affairs Certificate. She began her career in the medical device industry, where she managed complex 510k submissions, regulatory strategies for AI/ML based product features, and international regulatory submissions to federal authorities. Jain is an alumnus of the UW BRAMS program. She also holds a master’s degree in applied microbiology and biotechnology from India.

Noémi Kreif

Education:

  • PhD in Health Economics, London School of Hygiene and Tropical Medicine (LSHTM), University of London (UK)
  • MA in Economics, Central European University, Hungary
  • MSc in Economics, Corvinus University of Budapest, Hungary; Rajk Laszlo College for Advanced Studies, Hungary

Research Interests:

  • Causal inference methods for cost-effectiveness analysis and health policy evaluation
  • Quantitative evaluation of national health policy reforms
  • Incorporating machine learning in health policy evaluation, and health economics and outcomes research
  • Personalized/stratified decision making

Selected Publications

Google Scholar: https://scholar.google.com/citations?user=L7MMYvwAAAAJ&hl=hu  

Philip Hansten

Education

  • Doctor of Pharmacy (University of California San Francisco, 1967)

Courses Taught

  • Pharm 508 (Philosophy of Drug Interactions)

Research Interests

  • Drug Interactions
  • Philosophy of Science (as applied to drug therapy)
  • Philosophy (Friedrich Nietzsche, Michele de Montaigne, Stoicism, Epicureanism, Ernest Becker)

Biography

After graduating from UCSF, Dr. Hansten held positions in the Division of Clinical Pharmacology at Stanford University School of Medicine (working on drug interaction research with Professor Stanley N. Cohen) and at Washington State University. He joined UW in 1989. His books on drug interactions have sold over one million copies since 1971 and have been translated into 7 languages. He has lectured widely on drug interactions in North America, and given more than 50 lectures in Europe, Asia, Latin America, and the Middle East. He was a contributing editor to The Medical Letter for many years. He was a founding member of the American College of Clinical Pharmacy, and received teaching awards from students at the University of Washington and Washington State University. He gave the 2007 commencement address at the UCSF School of Pharmacy:

http://www.youtube.com/watch?v=rWEsIF7yk_4

Hansten works in the field of philosophy as well, and has taught philosophy of science at UW and UCSF since 2003. He also has written essays on philosophy and the history of ideas for the Ernest Becker Foundation: http://thedenialfile.wordpress.com/author/leucocephalus74/ and several humanities professors at other universities have assigned his YouTube presentation on Stoic Philosophy to their students: http://www.youtube.com/watch?v=3aFNCkoLzDk

Webinars and Videos

Tamoxifen Drug Interactions:  https://youtu.be/hxdNdKLKHww
Hyponatremia From SSRI/SNRI +Thiazides: https://youtu.be/tYr2tCypZOg
William K. Clifford’s Best Idea: https://youtu.be/UvKMkKuw8ek?si=DIWl0wIvs2e7tNxX

Selected Recent Publications

Gómez-Lumbreras A, Boyce RD, Villa-Zapata L, Tan M, Hansten PD, Horn J, Malone DC. Drugs that interact with colchicine via inhibition of cyrochrome P450 3A4 and P-glycoprotein: a signal detection analysis using a database of spontaneously reported adverse events (FAERS). Ann Pharmacother. 2023;57:1137-1146.

Hansten PD, Tan MS, Horn JR, Gomez-Lumbreras A, Villa-Zapata L, Boyce RD, Subbian V, Romero A, Gephart S, Malone DC. Colchicine drug interaction errors and misunderstandings: Recommendations for improved evidence-based management. Drug Safety. 2022;46:223-242.

Villa Zapata Boyce RD, Chou E, Hansten PD, Horn JR, Gephart SM, Subbian V, Romero A, Malone DC. QT Prolongation with the use of hydroxychloroquine and concomitant arrhythmogenic medications: A retrospective study using electronic health records data. Drugs Real World Outcomes. 2022;5:1-9.

Villa Zapata L, Carhart BS, Horn JR, Hansten PD, Subbian V, Gephart S, Tan M, Romero A, Malone DC. Serum potassium changes due to concomitant ACEI/ARB and spironolactone therpy: A systemic review and meta-analysis. Am J Health Syst Pharm. 2021;78:2245-2255.

Villa Zapata L, Hansten PD, Panic J, et al. Risk of bleeding with exposure to warfarin and nonsteroidal anti-inflammatory drugs: a systematic review and meta-analysis. Thomb Haemost. 2020: 120:1066-1074.

Villa Zapata L, Hansten PD, Horn JR, et al. Evidence of Clinically Meaningful Drug-Drug Interaction with concomitant use of colchicine and clarithromycin. Drug Safety. 2020:43:661-668.

Hansten PD. The underrated risks of tamoxifen drug interactions. Eur J Drug Metab Pharmacokinet 2018;43:495-508.

Jessica Beers

Education:

  • Postdoctoral Fellowship, University of Washington School of Pharmacy
  • Doctor of Philosophy (PhD) in Pharmaceutical Sciences, University of North Carolina at Chapel Hill
  • Doctor of Pharmacy (PharmD), Lipscomb University College of Pharmacy

Biography:
Dr. Beers is an assistant professor in the Department of Pharmacy at the University of Washington. Dr. Beers is passionate about drug safety in understudied populations, and her past research has focused on precision medicine, drug-induced liver injury, and using in vitro systems to predict drug metabolism and toxicity. Dr. Beers’ current work combines basic and translational research to investigate drug metabolism and disposition in pregnancy and lactation.

Publications: NIH

Clayton English

Education:

  • Bachelor of Science in Pharmacy Studies, University of Connecticut
  • Doctor of Pharmacy, University of Connecticut
  • MS in Health Services – Clinical and Translational Research, University of Washington

Research and Clinical Interests:

  • Psychiatric Pharmacy
  • Clinical Psychopharmacology
  • Drug-Induced Disease
  • Deprescribing
  • Mood Disorders
  • Adult ADHD
  • Psychostimulant Use
  • Interprofessional Education

Biography

Dr. Clayton English is an Assistant Professor of Pharmacy at the University of Washington School of Pharmacy. Clayton earned his Bachelor of Science and Doctor of Pharmacy degrees from the University of Connecticut in Storrs, Connecticut and subsequently completed a specialty residency in psychiatric pharmacy practice and clinical psychopharmacology at Nova Southeastern University College of Pharmacy in Fort Lauderdale, Florida. He holds board certifications in Psychiatric Pharmacy (BCPP), Pharmacotherapy (BCPS), and Geriatric Pharmacy (BCGP). From 2010 to 2022, Clayton served as a faculty member at Albany College of Pharmacy and Health Sciences (ACPHS) and practiced as a clinical pharmacy specialist in psychiatry at the University of Vermont Medical Center (UVMMC) in Burlington, Vermont. During his time in Vermont, Clayton helped expand clinical pharmacy services within inpatient psychiatry at UVMMC and precepted and assisted in the training of numerous students and residents in both pharmacy and psychiatry. Additionally, Clayton was highly involved in the didactic instruction of neuropsychiatric therapeutics and psychopharmacology across the pharmacy school curriculum.

Clayton has broad clinical and research interests in neurologic and psychiatric pharmacy including safe and appropriate use of psychiatric medications, psychotropic deprescribing, pharmacovigilance, mood disorders, adult ADHD, and drug-induced behavioral disorders. Additionally, Clayton is passionate about interprofessional education, team-based care, and student and resident well-being.

Clayton remains highly engaged in the professional development of pharmacists and enjoys participating in activities and organizations that advocate for the profession. Clayton is an active member of the American Association of Psychiatric Pharmacists (AAPP) and serves as a Senior Editor for the AAPP Psychiatric Pharmacotherapy Review Book and Course. He has been honored for his contributions to the profession and education of students and residents. He was the recipient of the Award of Excellence in Academic Teaching from the University of Vermont Psychiatry Residency Program in 2012, 2017, and 2019 and was recognized in 2013 as the Vermont Pharmacist of the Year by the Vermont Society of Health-Systems Pharmacists. Additionally, he was recognized as the ACPHS Preceptor of the Year in 2015 and Teacher of the Year of the ACPHS Vermont Campus in 2017 and 2021. Outside the classroom, Clayton enjoys exercising, road trips, spending time with his family, and exploring the greater Seattle area for the best coffee around.

Selected Publications

English C, Bode L. Major Depressive Disorder. In: Pharmacotherapy Self-Assessment Program, 2022 Book 3. Behavioral Health. Lenexa, KS: American College of Clinical Pharmacy, 2022.

English C. Depression. In: 2020-2021 Psychiatric Pharmacotherapy Review Course. College of Psychiatric & Neurologic Pharmacists. Lincoln: CPNP; 2020.

English C, Goodwin H, Dickinson JA, Rey JA. Brexanolone: A novel treatment option for postpartum depression. P&T. 2019;44(11):732-736.

Runyan S, Gething M, English C, Rabinowitz T. Pharmacotherapeutics. In: Fundamentals of Consultation Liaison Psychiatry: Neuropsychiatry. 1st ed. Nova Science Pub Inc; 2019.

DiSciullo AA, English CD, Horn WT. Modafinil Induced Psychosis in a Patient with Bipolar 1 Depression. Case Reports in Psychiatry. 2018;2018:3.

English CD. New therapeutic options for the management of ADHD. US Pharm. 2018;43(5):1-10.

Boyd JT, English C, Lounsbury KM. Antiparkinson Drugs. In: Dowd FJ, Johnson BS, Mariotti AJ. Pharmacology and Therapeutics for Dentistry. 7th ed. St. Louis: Elsevier; 2017.

English C, Aloi JJ. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
Clin Ther. 2015;37(4):691-715.

Harrington CA, English C, Schaefer S. Systematic review of the post-marketing surveillance of paliperidone. Journal of Symptoms and Signs. 2014;3(1):39-49.

English C, Rey JA, Schlesselman LS. Prevalence of hazardous alcohol use among pharmacy students at nine U.S. schools of pharmacy. Pharmacy Practice (Internet) 2011 Jul-Sep;9(3):162-168.

Harrington CA, English C. Adverse drug events related to ziprasidone: a meta-analysis of randomized, placebo-controlled trials. Pharmacotherapy 2011;31(9):840-849.

Kyu Lee

Education

  • PhD, Health Policy (Decision Science Track), Stanford University, 2020
  • MS, Health Service and Research, University of Minnesota, 2014
  • BS, Life science, Pohang University of Science and Technology, South Korea, 2012

Research Interests

  • Cost-effectiveness analysis
  • Disease burden forecasting
  • Infectious diseases
  • Optimizing vaccine virus selection
  • Simulation modeling methods

Biography

Kyu Lee, PhD, is a decision scientist and her research focuses on using disease simulation models to leverage scarce data in forecasting the future burden of disease and in evaluating the value of innovative health technology in many contexts including low- and middle-income countries. Her past research investigated the temporal trend in heavy drinking behaviors and features of Hepatitis C virus epidemiology observed in China. Her recent research project examined the impact of COVID-19 non-pharmaceutical interventions on the population immunity and future flu epidemics in the United States. Dr.Lee currently develops projects on estimating the impact of new vaccine technologies (e.g. cell-based, recombinant, and mRNA vaccines) on the future burden of respiratory infectious diseases such as flu and RSV, using mathematical models.

Selected Publications

Google Scholar

Lori Martell

Courses taught

  • PHRMRA 546 Technical Writing for Biomedical Regulatory Affairs
  • PHRMRA 548 Practicum
  • PHRMRA 550 Advanced Technical Writing for Biomedical Regulatory Affairs

Biography

Lori Martell is an affiliate assistant professor in the Department of Pharmacy and has been the senior director of medical writing for several Seattle-area immuno-oncology biotechnology companies. She began her research career in neurotransmitter-mediated cell signaling at the University of Michigan Medical School, and after completing a doctorate in pharmacology she collaborated with neurosurgery colleagues to establish the Brain Tumor Research Laboratory. Martell has worked for over 20 years in the biopharmaceutical industry for both startup biotechnology and global pharmaceutical companies, supporting regulatory and clinical document development primarily for novel therapies in oncology.

Jing Li

Education

  • PhD, Health Policy (Economics Track), University of California at Berkeley, 2016
  • MS, Economics, University of California at Berkeley, 2015
  • MA, International Comparative Education, Stanford University, 2009
  • BA, Economics and English, Peking University, China, 2008

Courses Taught

  • HEOR 597: Graduate Seminar
  • HEOR 598: HEOR Methodologies Seminar

Research Interests

  • Decision-making in Aging
  • Physician Behavior
  • Policy Evaluation
  • Experimental and Quasi-experimental Methods

Biography

Dr. Jing Li is a health economist with research interests in the economic, social and behavioral factors affecting individual decision-making in health and healthcare, for both providers and patients, and the impact of policies that leverage these factors to improve patient outcomes and healthcare market efficiency. Methodologically, she is interested in innovatively applying advanced experimental and econometric methods to addressing understudied questions in health economics and policy. Dr. Li’s current projects study experimentally measured social preferences (altruism) of physicians and their relationship with patient outcomes, healthcare and financial decision-making for older adults with cognitive impairments including Alzheimer’s disease and related dementias, and conflicts of interest in physician drug prescribing.

Selected Publications

https://www.ncbi.nlm.nih.gov/myncbi/jing.li.13/bibliography/public/

Parth Shah

Education

  • Postdoctoral Research Fellow, The Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC, 2018
  • Ph.D., Health Behavior, University of North Carolina, Chapel Hill, 2017
  • Pharm.D., University of Southern California, Los Angeles, 2012
  • B.S., Biochemistry, University of Southern California, Los Angeles, 2008

Bio

Dr. Parth Shah is a behavioral scientist and pharmacist who integrates these two disciplines to study and improve clinical practice and health policy in the delivery of cancer care. Dr. Shah’s research focuses on how pharmacies can be better used to provide cancer prevention and care services to their communities, such as HPV vaccinations for adolescents and colorectal cancer screenings for adults. His research interests also include medical and end-of-life decision-making and improving palliative care.

Teddy Johnson

Biography

Teddy Johnson is a clinical associate professor in the UW School of Pharmacy, the Director of Technology Development and Co-Director of the Pilot Awards Program at the Institute of Translational Health Sciences, and a licensed professional engineer in the state of California. He joined the healthcare community 30 years ago and has served start-up and Fortune 500 companies in research, design, clinical, marketing, and sales leadership roles; developing imaging, interventional, surgical, and digital health products. Over the years, Teddy has celebrated 2 IPO’s and 4 acquisitions, while earning numerous patents and commercializing dozens of new products worldwide. To foster the next generation of innovators, Teddy teaches in the Biomedical Regulatory Affairs Master of Science (BRAMS) program at the University of Washington and advises startup CEOs in Seattle, Vancouver, and Silicon Valley.

Mary Lessig

Courses taught

  • PHRMRA 524: Introduction to Clinical Trials
  • PHRMRA 525: Implementation & Conduct of Clinical Trials
  • PHRMRA 526: Project Management & the Business of Clinical Trials

Biography

Mary Lessig is an affiliate assistant professor in the Department of Pharmacy and works in Clinical Operations for a Seattle-area immuno-oncology biotechnology company. She has over 20 years of experience in clinical research. Lessig started her career in a nonclinical research laboratory and then moved to work in an academic clinical research office. After graduating from the University of Florida with a degree in biological psychology, she worked in clinical research coordinator and research quality assurance specialist roles at UF, the University of Washington and a community-based hospital before joining industry. Lessig is an alumnus of the UW BRAMS program.

Sepideh Varon

Education

  • Doctor of Philosophy (PhD), Health Services Research, University of California, Los Angeles (UCLA)
  • MPH, Health Services Research, Boston University
  • Bachelor’s degree in Psychology, University of California, Los Angeles (UCLA)

Jennifer Whiteley

Education

  • EdD, Health & Behavior, Columbia University
  • MSc, Epidemiology, London School of Hygiene and Tropical Medicine
  • MA, Physiology, Columbia University

Abby Winter

Education

  • Doctor of Pharmacy (PharmD), Drake University
  • Master of Public Administration (MPA), Drake University
  • PGY-1 Community Pharmacy Residency (Ambulatory Care Focus), Creighton University
  • Certified Diabetes Care and Education Specialist (CDCES)

Research Interests

  • Diabetes
  • Geriatrics (Deprescribing, Ageism)
  • Pharmacy Education, Scholarship of Teaching and Learning
  • Interprofessional Education (IPE)

Courses Taught

  • PY3 Pharmacist Provider Series (PHRMCY 547, PHRMPR 517)
  • Diabetes Care (PHARM 588)
  • Pharmacotherapeutics for Older Adults (PHARM 549)
  • Pharmacotherapeutics III and VI (PHRMCY 533, PHRMCY 536)

Biography

Dr. Abby Winter is an Associate Teaching Professor of Pharmacy and is the Assistant Director for Outreach in the Plein Center for Aging. She leads the clinical and outreach efforts of the Plein Center at Era Living, a group of Seattle-area assisted living communities. She teaches in various geriatrics and diabetes courses with the Schools of Pharmacy and Nursing at UW.

Dr. Winter earned her Doctor of Pharmacy and Master of Public Administration degrees at Drake University in Des Moines, Iowa, and completed a PGY-1 Community Pharmacy Residency with a focus in Ambulatory Care and Academia at Creighton University in Omaha, Nebraska.

She is a Certified Diabetes Care and Education Specialist (CDCES, formerly CDE). Prior to working at the UW School of Pharmacy, she practiced as a Clinical Pharmacist at the University of Washington Medicine Diabetes Institute and Lipid Clinic, and prior to that was a Clinical Assistant Professor in Ambulatory Care at the University of Kansas School of Pharmacy (KU) and served as a Residency Program Director (RPD) for a PGY-1 Community Pharmacy Residency Program.

Dr. Winter’s research interests include medication management in older adults, ageism, deprescribing, diabetes, interprofessional education (IPE), and the scholarship of teaching and learning.

Dr. Winter serves on the School’s APPE Advisory Group as the Ambulatory Care Representative, the Chair of the School’s Curriculum Committee, and is a member of the IPE Planning Committee. She is also a Director in the American Society of Consultant Pharmacists (ASCP) Washington Chapter.

Jasmine Mangrum

Education

  • PharmD, University of Iowa
  • Master of Public Health, University of Iowa
  • Bachelor of Arts in Public Health Education and Promotion, University of Iowa

 

Ali Bouge

Course taught

  • PHRMRA 548 Practicum

Biography

Ali Bouge is a teaching associate professor in the Department of Pharmacy and Director of the BRAMS Practicum. She’s earned the Regulatory Affairs Certification (RAC) and has gained extensive experience in the field of biomedical regulatory affairs, particularly with Investigational New Drug applications and Institutional Review Boards (IRBs). She has worked for IRBs at Stanford University, the University of Michigan and the Quorum Review, and co-directed the Clinical Trials Program at Stanford University within the Department of Pediatrics, Stem Cell and Gene Therapy. Ali Bouge is Executive Director of regulatory affairs for Exegenesis Bio. Her work puts her at the forefront of new developments in regulatory affairs and clinical trials in the area of gene therapy. Bouge is an alumnus of the UW BRAMS program.

Sharon Wu

Education

  • BA in Molecular & Cell Biology, University of California, Berkeley
  • PharmD, University of California, San Diego
  • PGY-1 Pharmacy Practice Residency, UW Medicine
  • PGY-2 Ambulatory Care and Academia Residency, Pacific University SOP/Virginia Garcia Memorial Health Center

Courses Taught

  • PHRMCY 544-546: Pharmacist Provider Readiness IV-VI
  • PHRMPR 532: Pharmacist Provider Experience Year II
  • PHRMCY 551: Case Conferences and Continuous Professional Development
  • PHRMCY 534: Pharmacotherapeutics (Asthma and Osteoarthritis)

Biography

Dr. Wu is an Associate Teaching Professor with experience teaching and coordinating courses in diverse areas, including Endocrine, Immunology, and Pulmonology. She currently serves as a co-course director for the PY2 Pharmacist Provider Series, which focuses on developing communication and clinical reasoning skills in both the skills lab and experiential settings to support outpatient and ambulatory care. In addition, she is a co-course director for the fourth-year longitudinal Continuous Professional Development course.

Dr. Wu is a Board Certified Ambulatory Care Pharmacist with experience managing underserved patients with chronic conditions, including diabetes, hypertension, cardiovascular risk, and asthma/COPD. Her clinical interests include diabetes, pulmonology, and solid organ transplantation, and her scholarship focuses on teaching and learning in pharmacy education, health and wellness, professional identity formation, and reimbursement for pharmacy services.

Dr. Wu serves as Faculty Director of the UWSOP STEP Program for high school students and as the 2025-2026 Chair of the School’s Academic Progress Committee. She also serves on various national committees and task forces within the American Association of Colleges of Pharmacy (AACP) and the American College of Clinical Pharmacy (ACCP).

Lauren Cirrincione

Education

  • Doctor of Pharmacy (PharmD), University of Pittsburgh
  • Master of Public Health (MPH), University of Nebraska Medical Center

Courses Taught

  • PHRMCY 535: Pharmacotherapeutics V

Biography

Dr. Cirrincione is an Associate Professor in the Department of Pharmacy at the University of Washington in Seattle, Washington, USA. Dr. Cirrincione’s research program addresses mechanisms of hormone-mediated drug interactions, focusing on clinical, translational pharmacology in transgender medicine. Dr. Cirrincione holds a Doctor of Pharmacy degree from the University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA, and a Master of Public Health in epidemiology from the University of Nebraska Medical Center, Omaha, Nebraska, USA. Dr. Cirrincione completed a clinical pharmacology fellowship in HIV at the University of Nebraska Medical Center, Omaha, Nebraska, USA.

Selected Publications

https://www.ncbi.nlm.nih.gov/myncbi/lauren.cirrincione.1/bibliography/public/

William Canestaro

Education

  • Doctor of Philosophy (PhD), Pharmaceutical Outcomes Research and Policy, University of Washington
  • Master of Science (M.Sc.), Medical Anthropology, University of Oxford

Douglas Barthold

Education:

  • PhD, Economics, McGill University

Research Interests:

  • Health policy and healthy aging
  • Chronic disease management
  • Alzheimer’s disease and dementia prevention and management
  • Disparities in utilization and effectiveness of pharmaceutical therapies
  • Pharmacist regulations
  • Health insurance design

Courses Taught:

  • Health Economics

Biography:

Douglas Barthold is a health economist and Associate Professor at the University of Washington, specializing in the intersection of health policies, healthcare utilization, and health outcomes, with particular focus on aging, dementia, and prescription drug policy. He is faculty at the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, serves as Co-Director of the Program in Health Economics and Outcomes Research Methodology (PHEnOM), and is a Board Member of the Washington State Prescription Drug Affordability Board. His research explores how health insurance design and prescription drug costs impact management of chronic diseases, including mid-life risk factors for dementia. Barthold holds a Ph.D. in Economics from McGill University and previously did postdoctoral research at the Schaeffer Center for Health Policy and Economics at the University of Southern California.

Selected Publications:

https://sites.google.com/site/douglasbarthold/peer-reviewed-publications

Maria Agapova

Courses taught:

  • PHRMRA 528 Medical Risk Analysis & Management
  • PHRMRA 548 Practicum

Biography

Maria Agapova is an affiliate assistant professor in the Department of Pharmacy, she has helped teach the Medical Risk Analysis & Management course since 2013 and is a faculty advisor for Practicum. As a health economics and outcomes research medical affairs professional, Maria currently works at Gilead Sciences. She previously held similar roles at AbbVie and Teva Pharmaceuticals. Maria is also an affiliate faculty at the UW CHOICE Institute.

David Hammond

Education

  • MS in Biomedical Regulatory Affairs, University of Washington

Courses taught

  • PHRMRA 524: Introduction to Clinical Trials
  • PHRMRA 525: Implementation & Conduct of Clinical Trials
  • PHRMRA 526: Project Management & the Business of Clinical Trials
  • PHRMRA 527: International Regulatory Affairs
  • PHRMRA 548: Practicum
  • PHRMRA 554: Advanced Medical Products Regulation I

Biography

David Hammond is the Director of the BRAMS program, teaching associate professor in the Department of Pharmacy, and the lead for the Clinical Trials Certificate. He holds a Regulatory Affairs Certification in Medical Devices (RAC), the Certified IRB Professional (CIP), the Certified Clinical Research Professional (CCRP) and a number of other industry certifications. Hammond is the chair of an institutional review board and serves as a consultant to several biotechnology companies, providing guidance on regulatory strategy, clinical trial design and operations, and compliance with the FDA and other regulatory bodies around the world. He currently serves on the board of the Organization of Regulatory and Clinical Associates (ORCA) and was the inaugural recipient of the Martha Feldman Award for service and education to the regulatory community. Hammond is an alumnus of the UW BRAMS program.

Catherine Yeung

Education

  • PharmD (University of Michigan)
  • PhD, Medicinal Chemistry (University of Washington)
  • MPH, Epidemiology (University of Washington)

Research Interests

  • Optimizing medication use in patients with Chronic Kidney Disease
  • Microfluidic models of kidney function in health and disease
  • Effects of uremia on drug transport and pharmacokinetics
  • Effects of microgravity on kidney structure and function

Courses Taught

  • PHARM 560
  • PHARM 579
  • PHARM 301
  • PCEUT 586
  • PCEUT 506
  • PHARBE 522

Biography

Dr. Yeung’s research includes both basic science and translational studies, and spans from the determination of molecular mechanisms of altered drug metabolism using 3-dimensional cell culture techniques to the evaluation of the effect of drugs and nutritional supplements on health outcomes in patients receiving hemodialysis. She is a key investigator in the development of a “kidney on a chip” microphysiological system that can be used in preclinical drug development.

Selected Publications

  • Kidneys on Chips: Emerging Technology for Preclinical Drug Development (PMID: 30274990)
  • Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity (PMID: 29202460)
  • Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis (PMID: 28675584)
  • Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport (PMID: 24132209)
  • Development of a microphysiological model of human kidney proximal tubule function (PMID: 27521113)

H. Steve White

Education:

  • BSci, Pharmacy,
  • MS, Pharmacology
  • PhD, Pharmacology

Courses Taught:

  • Pharm 531

Research Interests:

  • Early discovery of Anti-seizure drugs
  • Animal seizure and epilepsy models for drug discovery
  • Pharmaco-resistant epilepsy
  • Impact of adherence on seizure control
  • comorbidities of epilepsy
  • Prevention and disease modification of epilepsy
  • Role of the community pharmacist in the chronic management of the patient with epilepsy

Biography:

H. Steve White, RpH, Ph.D, earned his baccalaureate degree in Pharmacy and a M.S. in Pharmacology at Idaho State University. He earned his Ph.D. in Pharmacology at the University of Utah where he rose through the academic ranks after joining the College of Pharmacy faculty in 1986.

Before joining the University of Washington School of Pharmacy as Chair of the Department of Pharmacy, White was the principal investigator and scientific director of the NIH-sponsored Anticonvulsant Drug Development (ADD) Program, established in 1975 to identify novel anticonvulsant drugs using established animal seizure and epilepsy models.

White’s research is focused on understanding the factors that contribute to the initiation, propagation, and amelioration of seizure activity.

White has been the recipient of significant research funding from the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), and he and his collaborators have published over 170 original papers pertaining to the mechanism of action and the pharmacology of antiepileptic drugs. In addition to his academic service, he served as Research Director of CURE (Citizen’s United for Research in Epilepsy), the largest non-governmental provider of epilepsy research funding, from November 2011 until October of 2015, where he assisted in the development of strategic programs that advance transformative epilepsy research that may someday lead to a cure or disease modifying therapy for the patient at risk for developing epilepsy. He continues to serve as a Research Advisor to CURE’s team-science initiatives. He has been a co-organizer of two NIH-sponsored workshops on models of refractory epilepsy and epileptogenesis and currently serves on the organizing committee of the biannual Eilat Conferences on Antiepileptic Drug Development. Additionally, White has been actively engaged as a mentor for the next generation of neuroscientists and epilepsy educators and is frequently invited to speak at national and international congresses.

In 2011, White received an Honorary Doctor of Science from The University of Copenhagen Faculty of Pharmaceutical Sciences, Copenhagen, Denmark. In 2014, he was named the 2014 recipient of the Epilepsy Foundation’s Lifetime Accelerator Award, in recognition of his commitment and pioneering contributions to the field of epilepsy and seizures.

White was appointed as the new chair for the Department of Pharmacy in January, 2016.

Selected Publications:

https://www.ncbi.nlm.nih.gov/pubmed/?term=H.+Steve+White

Brian Werth

Education

  • PharmD, University of New Mexico

Research Interests

  • Mechanisms of resistance to antibiotics
  • Antimicrobial pharmacodynamics
  • Antimicrobial resistance, cross-resistance, and synergy
  • Staphylococcal infections

Courses Taught

  • PHRMCY 533: Pharmacotherapeutics III; disorders of the cardiovascular, pulmonary, renal, and endocrine systems

Biography

Dr. Werth received his PharmD from the University of New Mexico before completing a pharmacy practice residency at The Queen’s Medical Center in Honolulu, HI. He then completed an Infectious Diseases Pharmacotherapy Fellowship at Wayne State University in Detroit, MI before joining the University of Washington Department of Pharmacy as an Assistant Professor in 2013.

Dr. Werth’s research interest is in antimicrobial resistance and the pharmacokinetics and pharmacodynamics of antimicrobials. His interdisciplinary translational research program is primarily focused on understanding the mechanisms of cross-resistance among glycopeptides, lipopeptides, and lipoglycopeptides in Methicillin-Resistant Staphylococcus aureus (MRSA).

 

Selected Publications

https://www.ncbi.nlm.nih.gov/pubmed/?term=werth+BJ

  • Zhang R, Barreras Beltran IA, Ashford NK, Penewit K, Waalkes A, Holmes EA, Hines KM, Salipante SJ, Xu L, Werth BJ. Synergy Between Beta-Lactams and Lipo-, Glyco-, and Lipoglycopeptides, Is Independent of the Seesaw Effect in Methicillin-Resistant Staphylococcus aureus. Front Mol Biosci. 2021 Sep 9;8:688357. doi: 10.3389/fmolb.2021.688357. PMID: 34646861; PMCID: PMC8503943.
  • Shen T, Hines KM, Ashford NK, Werth BJ, Xu L. Varied Contribution of Phospholipid Shedding From Membrane to Daptomycin Tolerance in Staphylococcus aureus. Front Mol Biosci. 2021 Jun 11;8:679949. doi: 10.3389/fmolb.2021.679949. PMID: 34179085; PMCID: PMC8226217.
  • Seni J, Mapunjo SG, Wittenauer R, Valimba R, Stergachis A, Werth BJ, Saitoti S, Mhadu NH, Lusaya E, Konduri N. Antimicrobial use across six referral hospitals in Tanzania: a point prevalence survey. BMJ Open. 2020 Dec 15;10(12):e042819. doi: 10.1136/bmjopen-2020-042819. PMID: 33323448; PMCID: PMC7745526.
  • Mbwasi R, Mapunjo S, Wittenauer R, Valimba R, Msovela K, Werth BJ, Khea AM, Nkiligi EA, Lusaya E, Stergachis A, Konduri N. National Consumption of Antimicrobials in Tanzania: 2017-2019. Front Pharmacol. 2020 Oct 30;11:585553. doi: 10.3389/fphar.2020.585553. PMID: 33192526; PMCID: PMC7662556.
  • Shen T, Penewit K, Waalkes A, Xu L, Salipante SJ, Nath A, Werth BJ. Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage. J Antimicrob Chemother. 2021 Jan 19;76(2):292-296. doi: 10.1093/jac/dkaa422. PMID: 33057715; PMCID: PMC8600019.
  • Werth BJ, Ashford NK, Penewit K, Waalkes A, Holmes EA, Ross DH, Shen T, Hines KM, Salipante SJ, Xu L. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2021 Jun;27(6):910.e1-910.e8. doi: 10.1016/j.cmi.2020.08.025. Epub 2020 Aug 28. PMID: 32866650; PMCID: PMC7914275.
  • Theuretzbacher U, Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, Jerse A, O’Donnell J, Unemo M, Van Bambeke F, VanScoy B, Warn P, Werth BJ, Franceschi F, Alirol E. Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea-challenges and opportunities. Clin Microbiol Infect. 2020 Dec;26(12):1630-1635. doi: 10.1016/j.cmi.2020.08.006. Epub 2020 Aug 13. PMID: 32798687.
  • Barbee LA, Dombrowski JC, Hermann S, Werth BJ, Ramchandani M, Ocbamichael N, Barash E, Golden MR. “Sex in the Time of COVID”: Clinical Guidelines for Sexually Transmitted Disease Management in an Era of Social Distancing. Sex Transm Dis. 2020 Jul;47(7):427-430. doi: 10.1097/OLQ.0000000000001194. PMID: 32541302; PMCID: PMC7448723.
  • Hines KM, Shen T, Ashford NK, Waalkes A, Penewit K, Holmes EA, McLean K, Salipante SJ, Werth BJ, Xu L. Occurrence of cross-resistance and β-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels. J Antimicrob Chemother. 2020 May 1;75(5):1182-1186. doi: 10.1093/jac/dkz562. PMID: 32016379; PMCID: PMC7869793.
  • Barbee LA, Soge OO, Morgan J, Leclair A, Bass T, Werth BJ, Hughes JP, Golden MR. Gentamicin Alone Is Inadequate to Eradicate Neisseria Gonorrhoea From the Pharynx. Clin Infect Dis. 2020 Nov 5;71(8):1877-1882. doi: 10.1093/cid/ciz1109. PMID: 31712813; PMCID: PMC7755014.
  • Hines KM, Waalkes A, Penewit K, Holmes EA, Salipante SJ, Werth BJ, Xu L. Characterization of the Mechanisms of Daptomycin Resistance among Gram-Positive Bacterial Pathogens by Multidimensional Lipidomics. mSphere. 2017 Dec 13. PMID 29242835.
  • Werth BJ, Jain R, Hahn A, Cummings L, Weaver T, Waalkes A, Sengupta D, Salipante SJ, Rakita RM, Butler-Wu SM. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2017 Aug 3. PMID 28782651
  • Werth BJ, Shireman LM. Pharmacodynamics of ceftaroline plus ampicillin Against Enterococcus faecalis in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2017 Jan 17. PMID 28096164.
  • Werth BJ. Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother. 2017 Jan 31. PMID 28158617
  • Hahn WO, Werth BJ, Butler-Wu SM, Rakita RM. Corynebacterium striatum: a multidrug resistant pathogen associated with increased parenteral antibiotic usage. Emerg Infect Dis. 2016 Nov 22. PMID 27767926
  • Werth BJ, Smith JR, Sakoulas G. New Guidelines Endorse Old Recommendations for Invasive Enterococcal Infections. Clin Infect Dis. 2016 May 8. PMID 27161781
  • Mather CA, Werth BJ, Sivagnanam S, SenGupta DJ, Butler-Wu SM. Rapid Detection of Vancomycin Intermediate Staphylococcus aureus (VISA) by Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS). J Clin Microbiol. 2016 Jan 13. PMID 26763961
  • Werth BJ, Hahn W, Butler-Wu SM, Rakita RM. Emergence of high-level daptomycin resistance in Corynebacterium striatum in two patients with left ventricular assist device infections” Microbial Drug Resistance. 2015 Nov 6 PMID 26544621
  • Sakoulas G, Kumaraswamy M, Nonejuie P, Werth BJ, Rybak MJ, Pogliano J, Rice LB, Nizet V. Differential Effects of Penicillin Binding Protein Inactivation on the Susceptibility of Enterococcus faecium to Daptomycin and Human Cathelicidin LL-37. Antimicrob Agents Chemother. 2015 July 20. PMID 26195528
  • Werth BJ, Abbott AN. The combination of ampicillin plus ceftaroline is synergistic against Enterococcus faecalis. J Antimicrob Chemother. 2015 May 7. PMID 25953804.
  • Werth BJ, Carreno JJ, Reveles KR. Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the united states from 1996-2010. Am J Infect Control. 2015 Mar 14. PMID: 25783865

David Veenstra

Education

  • PharmD, University of California, San Francisco
  • PhD in Pharmaceutical Chemistry, University of California, San Francisco

Research Interests

  • Precision medicine
  • Cost-effectiveness analysis
  • Managed care decision making

Courses Taught

  • Pharm 520: Introduction to Pharmacoeconomics
  • Pharm 542: Managed Care Pharmacy

Biography

Dr. Veenstra is a Professor in the Comparative Health Outcomes, Policy & Economics (CHOICE) Institute in the Department of Pharmacy at the University of Washington.

Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of precision medicine. His major research projects include evaluation of the cost effectiveness of population-level genomic screening, and evidence thresholds and preferences for precision medicine.

Dr. Veenstra’s research has been funded through grants from the National Human Genome Research Institute, Centers for Disease Control, and the National Cancer Institute.
He also has worked extensively with organizations such as the Academy of Managed Care Pharmacy (AMCP) and the Institute for Clinical and Economic Review (ICER) to further the practical application of cost-effectiveness analysis in managed care decision making.

Dr. Veenstra teaches courses in health economics and managed care and is an author of five book chapters and 240 peer-reviewed publications.

Recent Publications

  1. Guzauskas GF, Garbett S, Zhou Z, Schildcrout JS, Graves JA, Williams MS, Hao J, Jones LK, Spencer SJ, Jiang S, Veenstra DL*, Peterson JF*. Population Genomic Screening for Three Common Hereditary Conditions: A Cost-Effectiveness Analysis. Ann Intern Med. 2023 May;176(5):585-595. PMID: 37155986
  2. Lee W, Dayer V, Jiao B, Carlson JJ, Devine B, Veenstra DL. Use of real-world evidence in economic assessments of pharmaceuticals in the United States. J Manag Care Spec Pharm. 2021 Jan;27(1):5-14. PMID: 33377439
  3. Guzauskas GF, Basu A, Veenstra DL. Are there different evidence thresholds for genomic vs. clinical precision medicine? A VOI-based framework applied to antiplatelet drug therapy. Value in Health, 2019.
  4. Dhanda DS, Veenstra DL, Regier DA, Basu A, Carlson JJ. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment. J Manag Care Spec Pharm. 2020 Apr;26(4):529-537. PMID: 32223606
  5. Henderson LM, Robinson RF, Ray L, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL. VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clin Transl Sci. 2019 Mar 1. PMID: 30821933.

Sean D. Sullivan

Positions

Professor of Pharmacy, School of Pharmacy, Professor of Health Services, School of Public Health, University of Washington

Education

  • BSc.Pharm 1983 Oregon State University, College of Pharmacy
  • M.Sc. 1986 University of Texas, College of Pharmacy (Administrative and Economic Sciences)
  • Ph.D. 1992 University of California, Berkeley (Health Economics and Policy)

Research Interests

  • Pharmaceutical policy
  • Economic evaluation of pharmaceuticals
  • Global health technology assessment
  • Medical decision making

Courses Taught

  • HECON 530 – Practice of Healthcare Technology Assessment in a Global Environment
  • HEOR 545 – Topics in Pharmaceutical Policy
  • PHRMCY 515 – Population Health and Pharmacy Management

Biography

Sean D. Sullivan, BScPharm, MSc, PhD, is a Professor, School of Pharmacy and Visiting Professor, London School of Economics and Political Science. He holds a joint appointment as Professor of Health Services, School of Public Health. Dr. Sullivan was Dean of the School of Pharmacy from 2014 to 2022.

He completed training in pharmacy at Oregon State University in 1983, obtained a master’s degree at the University of Texas in 1986 and a PhD in health economics and policy at the University of California, Berkeley in 1992.

Dr. Sullivan has authored more than 450 articles, book chapters and reports. In many of these, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include health technology assessment, medical decision-making, and economic evaluation of medical technology, including pharmaceuticals. He is past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and past chair of the Academy of Managed Care Pharmacy (AMCP) Executive Committee of the Format for Formulary Submissions – the United States evidence-based guidelines for formulary decision making.

Dr. Sullivan was a member of the Medicare Evidence Development and Coverage Advisory Committee, Chair of the Regence Blue Shield and Premera Blue Cross P/T Committee, and Chair of the Premera Blue Cross Value Assessment Committee. He was awarded the 2014 Stephen G. Avey Lifetime Achievement Award from the Academy of Managed Care Pharmacy (AMCP), and the 2015 APhA Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award. In 2020, he was elected to the National Academy of Medicine and in 2022 was elected Fellow, American Association for the Advancement of Science (AAAS).

Selected Publications

  • Cousin EM, Sullivan SD, Gabriel N, Hansen RN, Hernandez I. Drugs Anticipated to Be Selected for Medicare Price Negotiation in 2025 for Implementation in 2027. J Manag Care Spec 2024 Nov;30(11):1203-1210. doi: 10.18553/jmcp.2024.24167.
  • Sullivan SD, Wouters OJ, Cousin EM, Kirihennedige A, Hernandez I. Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform Medicare Drug Price Negotiation. Value in Health 2024 Oct;27(10):1348-1357. doi: 10.1016/j.jval.2024.08.001.
  • Hernandez I, Wouters OJ, Cousin EM, Kirihennedige A, Sullivan SD. Interpreting the First Round of Maximum Fair Prices Negotiated by Medicare for Drugs. Health Affairs Forefront 2024 September 3, 2024 10.1377/forefront.20240830.863408
  • Wouters OJ, Sullivan SD, Cousin EM, Gabriel N, Papanicolas I, Hernandez I. Drug Prices Negotiated by Medicare vs US Net Prices and Prices in Other Countries. JAMA 2025 Jan 7;333(1):85-87. doi: 10.1001/jama.2024.22582.
  • Sullivan SD, Chaturvedi S, Gautam P, Arnaud A. Cost effectiveness of caplacizumab in Immune thrombotic thrombocytopenic purpura in the US. J Manag Care Spec 2024 Dec 23:1-12. doi: 10.18553/jmcp.2025.24271.
  • Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD. Overpayment for Generic Drugs under Medicare Part D: Consequences on Patient Out-of-Pocket Costs. JAMA Health Forum 2025; 6(2):e250012. doi:10.1001/jamahealthforum.2025.0012
  • Hernandez I, Gabriel N, Japinga M, Pathak Y, Hansen RN, Sullivan SD, Fendrick AM. Projected Out of Pocket Savings of the Medicare Part D Two Dollar Drug List. JAMA 2025 March 24 On-line doi:10.1001/jama.2025.2028
  • Jofre-Bonet M, McGuire A, Dayer V, Roth JA, Sullivan SD. The Price Effects of Biosimilars in the US. Value in Health 2025. https://doi.org/10.1016/j.jval.2025.02.008
  • Sullivan SD, Grueger J, Sullivan AP, Ramsey SD. The Consequences of Pharmaceutical Tariffs in the US. JMCP In press, May, 2025
  • Sun, L, Veenstra DL, Brufsky A, Pluard T, Sandin R, Stergiopoulos S, Liu J, Williams T, Sullivan SD. First Line CDK4/6 Inhibitors in Combination with Aromatase Inhibitors for HR+/HER2- Metastatic Breast Cancer: Real World Outcomes and Costs in a Medicare Population. J Manag Care Spec Pharm in press, 2025

Andy Stergachis

Education

  • PhD in Social & Administrative Pharmacy, University of Minnesota
  • MS in Pharmacy Administration, University of Minnesota
  • BPharm Pharmacy, Washington State University

Courses Taught

  • Pharm 581/GH 543: Global Health Pharmacy

Biography

Andy Stergachis is Professor of Pharmacy and Global Health and Adjunct Professor of Health Services and Epidemiology, and Director of the Global Medicines Program, University of Washington. He is an author of 237 peer-reviewed publications in areas such as drug safety, pharmaceutical outcomes, and clinical epidemiology. A licensed pharmacist, he served as Editor-in-Chief of the Journal of the American Pharmacists Association for 6 years until 2019. He is a member of the CEPI Maternal Immunization Working Group; Chair of the Scientific Advisory Board for the Pregnancy Registry to Assess the Safety of Antimalarial use in Pregnancy, and Member, Executive Board, Safety Platform for Emergency Vaccines (SPEAC), Brighton Collaboration, The Task Force for Global Health. He is an elected member of the National Academy of Medicine, and Fellow of the International Society for Pharmacoepidemiology, American Pharmacists Association, American Association for the Advancement of Science, Washington State Pharmacy Association, and the Washington State Academy of Science. Since 2010, He has chaired multiple student doctoral dissertation committees, mentored postdoctoral trainees, served as member of numerous graduate student PhD dissertation and MPH thesis committees, and served as advisor to multiple graduate students.
His research has made major contributions to advancing the safety of medications and vaccines. He has developed and evaluated novel approaches for safety surveillance of vaccines and essential medicines, including medicines for HIV/AIDS, as well as for the evaluating innovative pharmacy-based services in low- and middle-income countries. His recent projects include pharmacovigilance system strengthening; active safety surveillance of TB preventive therapy for PLHIV; sentinel site readiness for maternal immunization active safety surveillance; global burden of antimicrobial resistance; and evaluating and optimizing a virtual care model for PrEP delivery. He is currently PI of the University of Washington component of the Background Incidence Rates in Africa project funded by the Gates Foundation and co-investigator with several other global medicines projects, including with the Institute for Health Metrics and Evaluation on the global burden of antimicrobial resistance. Through his affiliation with the Northwest Center for Public Health Practice, he also works on workforce development and research in emergency preparedness with the public health community.

Selected Publications

  • Wittenauer R, Bacci J, Shah P, Stergachis A. Vaccination payments in states with provider status: a claims analysis. J Am Pharm Assoc (2003). 2025 Jan-Feb;65(1):102301. doi: 10.1016/j.japh.2024.102301. Epub 2024 Nov 23 1
  • Munoz FM, Kampmann B, Stergachis A, Chaudhary M, Cutland CL, Khalil A, Gentile A, Jones CE, Marshall H, Sevene E, Darko DM, Swamy G, Hyde TB, Voss G, Muelen AS. A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women. Vaccine. 2025 Jul 18;62:127513.
  • Bardach A, Brizuela M, Berrueta M, Ciapponi A, Sambade JM, Ballivian J, Ortega V, Castellana N, Comandé D, Parker EPK, Kampmann B, Stegelmann K, Xiong X, Stergachis A, Munoz FM, Buekens P, Mazzoni A. Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines. Hum Vaccin Immunother. 2025 Dec;21(1):2463191.
  • GBD 2021 Global Stillbirths Collaborators. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021. Lancet. 2024 Nov 16;404(10466):1955-1988. (co-author).
  • GBD 2023 Vaccine Coverage Collaborators. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037-2 (co-author)
  • Chaudhary M, Cutland CL, Bonet M, Gentile A, Jones CE, Marshall HS, Stergachis A, Voss G, Darko DM, Sevene E, Hyde T, Fairlie L, Kampmann B, Everett D, Munoz FM. Burden of Lassa fever disease in pregnant women and children and options for prevention. Vaccine. 2024 Nov 1;43:126479.
  • Ciapponi A, Berrueta M, Argento FJ, Ballivian J, Bardach A, Brizuela ME, Castellana N, Comandé D, Gottlieb S, Kampmann B, Mazzoni A, Parker EPK, Sambade JM, Stegelmann K, Xiong X, Stergachis A, Buekens P. Safety and Effectiveness of COVID-19 Vaccines during Pregnancy: A Living Systematic Review and Meta-Analysis. Drug Safety. Drug Saf. 2024 Jul 15.
  • Montaño MA, Chen Y, Saldarriaga EM, Thuo N, Kiptinness C, Stergachis A, Mugambi ML, Ngure K, Ortblad KF, Sharma M. Willingness to pay for HIV pre- and post-exposure prophylaxis services delivered via an online pharmacy in Kenya. BMC Health Serv Res. 2025 Apr 22;25(1):576. doi: 10.1186/s12913-025-12766-x. PMID: 40264148.
  • Chen Y, Montaño MA, Naik P, Thuo N, Kiptinness C, Rafferty M, Stergachis A, Mugambi ML, Ngure K, Ortblad KF, Sharma M. Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya. J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003680. Epub ahead of print. PMID: 40198924.
  • Sahu M, Wagner TD, Thomson A, Beauchamp M, Campbell JD, Crosby S, DeJarnatt D, Lescinsky H, Salih RK, Taylor K, Weil M, Dwyer-Lindgren L, Haakenstad A, Scott JW, Stergachis A, Essien UR, Dieleman JL. Variation in Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State. JAMA Health Forum. 2025 Aug 1;6(8):e252329.

Peggy Soule Odegard

Education

  • PharmD, University of Washington
  • Bachelor of Science in Pharmacy, UW

Research Interests

  • Practice advancement and diabetes

Courses Taught

  • Phrmcy 501: Foundations of Being a Pharmacist I
  • Phrmcy 502: Foundations of Being a Pharmacy II
  • Phrmcy 503: Advanced Pharmacy Leadership
  • Pharmacy 588: Diabetes Care
  • Pharmacy 557: Introduction to Therapeutics

Biography

Peggy Odegard, BS Pharm, PharmD, CDES, having served as the Interim Dean for the School of Pharmacy in 2022-2023, and an active pharmacist practitioner. She earned her Doctor of Pharmacy and Bachelor of Science in Pharmacy degrees from the University of Washington.

Dr. Odegard oversees the UW School of Pharmacy Doctor of Pharmacy program and is advanced diabetes care pharmacist clinician. She provides regular outreach and community-based education to older adults and to those affected by diabetes, mentoring students alongside her in this role. Her research and teaching are focused on diabetes care, pharmacy practice advancement, interprofessional education, and leadership. Dr. Odegard has published more than 60 refereed manuscripts and book chapters, and regularly presents her work nationally.

Dr. Odegard is past Chair of the UW School of Pharmacy, Department of Pharmacy and prior to her work at the UW, served as the Clinical Pharmacy Manager for a regional health system, where she gained substantial experience and training in organizational leadership, change management, and with quality improvement and implementation of pharmacy practice services.

Selected Publications

https://www.ncbi.nlm.nih.gov/pubmed/?term=odegard+ps

Teresa O’Sullivan

Education

  • BS Pharmacy, University Washington (1984)
  • PharmD, University of Minnesota (1990)

Research Interests

  • Teaching and learning in the practice setting
  • Assessment of national experiential education practices

Courses Taught

  • PHARM 509 Medical Literature Evaluation
  • PHARMP 541 Introductory Pharmacy Practice Experience in Clinic Skills
  • PHRMCY 511 Introduction to Evidence-based Practice

Biography

Teresa O’Sullivan obtained her Bachelor of Science in pharmacy from the University of Washington in 1984, and her Doctor of Pharmacy degree from the University of Minnesota in 1990. After completion of a research fellowship in clinical pharmacokinetics, she became the Director of Experiential Education at the University of Washington School of Pharmacy. She was board-certified as a pharmacotherapy specialist in 1993. Her teaching topics include medical literature evaluation, drug allergy, and practice-based education. She interacts regularly with the over 400 volunteer faculty and preceptors who teach the University of Washington Doctor of Pharmacy students. She conducts qualitative research in the area of practice-based learning, precepts pharmacy students in the Dental Clinics of the University of Washington School of Dentistry, and is an active member of the American Association of Colleges of Pharmacy.

 

Selected Publications

  • Kennie-Kaulbach N, Cooley J, Anksorus H, Janke KK, Riley B, O’Sullivan TA. A pharmacy preceptor development framework for nurturing learner professional identity formation. Am J Pharm Educ 2025;89():101862.
  • Cooley J, Kennie-Kaulbach N*, Crespo K, Anksorus H, Riley B, Williams C, O’Sullivan TA. Professional identity, pivotal moments and influences: implications for preceptor development. Curr Pharm Teach Learn 2025;17(6):102345.
  • Kennie-Kaulbach N*, Cooley J, Williams C, Riley B, Anksorus H, O’Sullivan TA. How preceptors influence pharmacy learner professional identity formation. Am J Pharm Educ 2024;88(9):100740.
  • O’Sullivan TA, Sy E, Bacci J. Essential attributes for the community pharmacist as care provider. Am J Pharm Educ (in press; currently available at: https://www.ajpe.org/doi/pdf/10.5688/ajpe7125).
  • O’Sullivan TA, Jefferson. Strategies for enhancing clarity and reader accessibility of qualitative research results. Am J Pharm Educ (in press; currently available at: https://www.ajpe.org/doi/pdf/10.5688/ajpe7124).
  • O’Sullivan TA, Sullivan L, Webber K, Weber SS. A pilot comparison of student outcomes between longitudinally- and traditionally-placed advanced pharmacy practice experiences. Am J Pharm Educ (in press; currently available at: https://www.ajpe.org/doi/pdf/10.5688/ajpe7143)
  • Assemi M, DiVall MV, Lee K, Sy E, O’Sullivan TA. Quality assurance and improvement practices of experiential education programs within US schools of pharmacy. Am J Pharm Educ 2019;83(3): Article 6582.
  • Christensen E, Webber K, Kelly JL, Weber SS, O’Sullivan TA. Quality improvement evaluation of a longitudinal institutional advanced pharmacy practice model. Innov Pharm 2018;9(3): Article 2.
  • O’Sullivan TA, Sy E. A qualitative study identifying key components to standardize across inpatient general medicine advanced pharmacy practice experiences. Am J Pharm Educ 2018;82(2): Article 6215.
  • Danielson J, Kraus C, Jefferson CG, Cleven AJ, Rice LE, O’Sullivan TA. Third party onboarding organizations as gatekeepers for student placement decisions. Am J Pharm Educ 2018;82(1): Article 6275.
  • O’Sullivan TA, Sy E, Bacci J. A qualitative study designed to build an experiential education curriculum for practice-ready community pharmacy-bound students. Am J Pharm Educ 2017;81(10): Article 6055.
  • O’Sullivan TA, Lau C, Sy E, Moogk H, Weber SS, Danielson J. Analysis of the student experience in an attending pharmacist model general medicine advanced pharmacy practice experience. Am J Pharm Educ 2017;81(4): Article 66.
  • O’Sullivan TA, Phillips J, Demaris K. Medical literature evaluation in US schools of pharmacy. Am J Pharm Educ 2016;80(1): Article 5.
    O’Sullivan TA, Lau C, Patel M, Mac C, Krueger J, Danielson J, Weber SS. Identifying measurable behaviors of exemplary pharmacy preceptors. Am J Pharm Educ 2015;79(10): Article 151.
  • Danielson J, Craddick K, Eccles D, Kwasnik A, O’Sullivan TA. Challenges facing pharmacy experiential education: a qualitative analysis of common concerns. Am J Pharm Educ 2015;79(1): Article 6.
  • O’Sullivan TA, Danielson J, Weber SW. Qualitative analysis of common definitions for core advanced pharmacy practice experiences. Am J Pharm Educ 2014;78(5): Article 91.

Leigh Ann Mike

Education

  • PharmD, University of Illinois at Chicago
  • Board Certified Pharmacotherapy Specialist (BCPS)
  • Board Certified Geriatric Pharmacist (BCGP)

Research Interests

  • Geriatrics
  • Deprescribing
  • Age-Friendly Care
  • Pharmacy Education, Scholarship of Teaching & Learning

Courses Taught

  • PHRMCY 541-543, PHRMPR 531 Pharmacist Provider Series
  • PHARM 548 Current Topics in Geriatrics
  • PHARM 550 Seminar in Geriatrics

Biography

Dr. Leigh Ann Mike is a Clinical Associate Professor of Pharmacy and Shirley & Herb Bridge Endowed Professor for Women in Pharmacy at the University of Washington. She is the Interim Director and Assistant Director for Education, both at the Plein Center for Aging. She completed her PharmD and PGY1 residency training at the University of Illinois at Chicago.

She is Board Certified as a Pharmacotherapy Specialist (BCPS) and as a Geriatric Pharmacist (BCGP). Her practice experiences have included Drug Information Specialist at Grady Health System in Atlanta, Georgia; Critical Care Pharmacist at Harborview Medical Center in Seattle, Washington; and Consultant Pharmacist at a Seattle-area assisted living community.

Her interests include the care of older adults in acute and critical care settings; humanizing/whole-person care; preparing a diverse pharmacy workforce to meet the healthcare needs of an increasingly diverse population of older adults; and developing Age Friendly Health Systems.

Selected Publications

  • English C, Bergeron K, Mike LA. Xanomeline/trospium combination for schizophrenia: treatment considerations for older adults. J Gerontol Nursing. 2025:51(6)7-12.
  • Mike LA, Hart LA. Pharmacotherapy. Self-assessment questions. In: Colburn JL, Westcott AM, Potter JF, eds. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. 12th American Geriatrics Society; 2025.
  • Mike LA, Marcum ZA, Gray SL. Assessing Health and Delivering Health Care to Older Adults. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: a Pathophysiologic Approach, 12th ed. New York, NY:McGraw-Hill; 2023.
  • Shiferaw MW, Zheng T, Mike LA, Chan LN.Assessing the accuracy and quality of artificial intelligence (AI) chatbot-generated responses in making patient-specific drug-therapy and healthcare-related decisions. BMC Med Inform Decis Mak 24, 404 (2024).
  • Do J, Choi SC, Chang, Mike LA. Creating a Win-Win: A Novel Layered Learning Approach for Assessing First-Year Pharmacy Students’ Communication Skills. Curr Pharm Teach Learn 2024 May 27;16(8):102111.
  • Mike LA, Toy JM, Chan L-N. Nutritional Supplements in Older Adults. In: Dong BJ, Elliott DE, eds. Ambulatory Care Self-Assessment Program, 2017 Book 3. Nutritional/Gastroenterologic Care. Lenexa, KS: American College of Clinical Pharmacy, 2017

John Horn

Research Interests

  • Drug interactions

Courses Taught

  • Pharmacy 561: Therapeutics II
  • Pharmacy 510: Clinical Applications of Drug Interactions

Biography

John Horn received his bachelor of pharmacy degree from Washington State University. He completed a clinical pharmacy residency at Deaconess Hospital in Spokane, Washington and obtained his Doctor of Pharmacy degree at the University of Cincinnati, Cincinnati, Ohio.

He has authored over 200 articles related to drug interactions. He is co-author of “The Top 100 Drug Interactions; A Guide to Patient Management,” a pocket-sized book of common drug interactions that is in its 13th edition. Dr. Horn has co-authored the reference text “Hansten and Horn’s Drug Interactions Analysis and Management” for over 20 years. “Drug Interactions Analysis and Management” is updated every three months and is recognized as the standard reference on drug interactions. These references have been translated into 5 languages and distributed to health care practitioners world-wide.

Dr. Horn is one of the founders of the Drug Interaction Foundation that has developed standardized methods of evaluating potential drug interactions and outcome-based criteria for rating the potential significance of drug interactions. He is a Fellow of the American College of Clinical Pharmacy and a member of the American Society of Health-Systems Pharmacists. He is currently chair of the Drug Interactions Specialty Panel for The Annals of Pharmacotherapy, a member of the editorial board of “Pharmacotherapy,” and serves as a reviewer for several medical and pharmaceutical journals.

Selected Publications

Horn JR, Gumpper KF, Hardy JC, McConnell PJ, Phansalkar S, Reilly C. Clinical decision support for drug-drug interactions: Improvement needed. Am J Health Syst Pharm. 2013 May 15;70(10):905-9.

Boyce RD, Horn JR, Hassanzadeh O, Waard Ad, Schneider J, Luciano JS, Rastegar-Mojarad M, Liakata M. Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness. J Biomed Semantics. 2013 Jan 26;4(1):5.

Boyce R, Collins C, Clayton M, Kloke J, Horn JR. Inhibitory Metabolic Drug Interactions with Newer Psychotropic Drugs: Inclusion in Package Inserts and Influences of Concurrence in Drug Interaction Screening Software.

Horn JR, Mantione MM, Johanson JF. OTC Polyethylene Glycol 3350 and the Pharmacist’s Role in Managing Constipation. J Am Pharm Assoc (2003). 2012 May-Jun;52(3):372-80.

Horn JR, Hansten PD, Osborn JD, Wareham P, Somani S. Customizing Clinical Decision Support to prevent excessive drug-drug interaction alerts. Am J Health Syst Pharm. 2011 Apr 15;68(8):662-4.

Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The Risk of Hypotension Following Co-prescription of Macrolide Antibiotics and Calcium Channel Blockers. CMAJ. 2011 Feb 22;183(3):303-7.

Mary Hebert

Education

  • PharmD, University of California, San Francisco
  • Residency
  • Fellowship

Research Interests

Her research focuses on a mechanistic understanding of changes in the clinical pharmacology of medications during pregnancy and lactation. She is a translational researcher and is able to bridge from basic science to clinical. Her research grants have included basic science work in drug metabolism and transport, animal work from rodent to the non-human primate and human work phase I to III. Her Obstetric-fetal Pharmacology Research Unit is a multidisciplinary program with collaborators from all 3 departments in the University of Washington School of Pharmacy as well as multiple departments outside of the School of Pharmacy.

Courses Taught

  • PHRMCY 531
  • PHRMCY 535
  • PHRMCY 536
  • PHRMCY 537
  • PHRMCY 516

Biography

Mary F. Hebert, Pharm.D., FCCP is a Professor of Pharmacy, Adjunct Professor of OBGYN, Director of the University of Washington Obstetric-Fetal Pharmacology Research Unit, Core Member of the University of Washington, Center for Ecogenetics and Environmental Health and Member of the University of Washington Institute of Translational Health Sciences. Dr. Hebert joined the University of Washington Faculty in 1996. She has a faculty appointment in the graduate school with an endorsement to Chair. Dr. Hebert has 30 years experience conducting clinical pharmacology research resulting in over 100 publications. She has a long-standing, well-funded, productive research program. She has been an invited speaker at many national and international conferences.

Her research focuses on a mechanistic understanding of changes in the clinical pharmacology of medications during pregnancy and lactation. She is a translational researcher and is able to bridge from basic science to clinical. Her research grants have included basic science work in drug metabolism and transport, animal work from rodent to the non-human primate and human work phase I to III. Her Obstetric-fetal Pharmacology Research Unit is a multidisciplinary program with collaborators from all 3 departments in the School of Pharmacy as well as multiple departments outside of the School of Pharmacy.

Dr. Hebert is a licensed pharmacist and preceptor. She has a wide range of pharmacy practice experience including practice in community retail pharmacy, community hospital pharmacy and tertiary care (adult, pediatric, inpatient (intensive care and floor patients) and outpatient clinic).

Selected Publications

Please see “My Bibliography” in the US National Library of Medicine for a list of publications at the following website:

http://www.ncbi.nlm.nih.gov/sites/myncbi/18swnaiXtFjQc/bibliography/49436592/public/?sort=date&direction=ascending

Tom Hazlet

Education

  • DrPH in Health Policy & Administration, University of California, Berkeley
  • PharmD, University of California, San Francisco
  • Bachelor of Science in Biology, University of Redlands

Research Interests

  • Regulation of medical products

Courses Taught

  • Pharm 516-518 Biomedical Regulatory Affairs
  • Pharm 532 Medical Products Policy Analysis
  • Pharm 543 Pharmacy Law & Ethics
  • Phrmra 548 BRAMS Practicum

Biography

1968-72 — Industrial microbiologist for a biologics manufacturer
1973-77 — University of California San Francisco — PharmD
1977-78 — Yale-New Haven Hospital — residency
1978-84 — UCLA Hospital — parenteral nutrition
1984-96 — Sutter Solano Hospital (part time after 1986)
1986-91 — University of California Berkeley — DrPH
1998-96 — California Department of Health Services; seconded to US Food and Drug Administration
1996-present — University of Washington School of Pharmacy
2007-present — Director, Biomedical Regulatory Affairs MS (BRAMS)

Selected Publications

  • Karwaki TE & Hazlet TK. A qualitative analysis of student-written law and ethics cases: A snapshot of PY2 student experience. CPTL. 2017
  • Hazlet TK, Karwaki TE, Downing DF. Pathway to pharmacist medical provider status in Washington State. J Am Pharm Assoc (2003). 2017 Jan – Feb;57(1):116-119.
  • Chan LN, Soltani H, Hazlet TK. Probiotics for neonates: safety for prime time questioned without regulatory changes. J Pediatr. 2015 Feb;166(2):502
  • Austin SC, Hammer D, Hazlet T, et al. An educational technology student and faculty needs assessment. PHARMACOTHERAPY 2012; 32(10): E287-E287

Ryan Hansen

Education

  • PhD in Pharmaceutical Outcomes Research and Policy, UW
  • PharmD, UW
  • Bachelor of Arts in Chemistry and Philosophy, Carroll College

Research Interests

  • Cost-effectiveness modeling
  • Comparative effectiveness research
  • Medication safety

Courses Taught

  • PHRMCY 512: Fundamentals of US Health Care, Pharmacy Safety and Law
  • HEOR 505: Managed Care Pharmacy
  • HEOR 530: Economic Evaluation in Health and Medicine
  • HEOR 532: Advanced Methods in Economic Evaluation
  • HEOR 545: Pharmaceutical and Medical Policy Evaluation
  • HEOR 597: Graduate Seminar

Biography
Dr. Hansen is Professor of Pharmacy and Chair of the Department of Pharmacy. His primary research interests focus on the comparative safety of prescription medications, health technology assessment, and health care system efficiency. He received his Bachelor of Arts from Carroll College, and his Doctor of Pharmacy and Doctor of Philosophy from the University of Washington.

Selected Recent Publications

Elsisi, Z, Canestaro WJ, Steuten L, Hansen RN. Applying Early Health Technology Assessment (e-HTA) to Inform Investment in Novel Health Technologies in the US. International Journal of Technology Assessment in Health Care 2025. In Press.

Gold LS, Heagerty PJ, Hansen RN, Friedly JL, Johnston SK, Deyo RA, Curatolo M, Turner JA, Rundell SD, Wysham K, Jarvik JG, Suri P. Adverse respiratory events during treatment with gabapentin and opioids among older adults with spine-related conditions: a propensity-matched cohort study in the US Medicare population. Spine 2025. In Press.

Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD, Fendrick AM. Projected Out of Pocket Savings of the Medicare Part D Two Dollar Drug List Model. JAMA 2025. In Press.

Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD. Overpayment for Generic Drugs under Medicare Part D: Consequences on Patient Out-of-Pocket Costs. JAMA Health Forum 2025;6(2):e250012.

Gold LS, Heagerty PJ, Hansen RN, Friedly JL, Johnston SK, Deyo RA, Curatolo M, Turner JA, Rundell SD, Wysham K, Jarvik JG, Suri P. Mortality after concurrent treatment with gabapentin and opioids in older adults with spine diagnoses. PAIN 2024. In Press.

Cousin EM, Sullivan SD, Hansen RN, Gabriel N, Kirihennedige AS, Hernandez I. Drugs Anticipated to Be Selected for Medicare Price Negotiation in 2025 for Implementation in 2027. Journal of Managed Care & Specialty Pharmacy 2024;30(11): 1203-1210.

Tran J, Mishra A, Zimmerman M, Hansen RN. Bridging PrEP Access Gaps: Mapping Geospatial Accessibility Across the US and Leveraging Community Pharmacies for Expansion. Journal of the American Pharmacists Association 2024. In Press.

Hernandez I, Sullivan SD, Hansen RN, Fendrick AM. Cheaper Isn’t Always Better: Drug Shortages in the U.S. and A Value-Based Solution to Alleviate Them. Journal of Managed Care & Specialty Pharmacy 2024;30(7):719-26.

Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Kubiniec RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug and Alcohol Dependence Reports 2024. In Press.

Green TC, Silcox J, Bolivar D, Gray M, Floyd AS, Irwin AN, Hansen RN, Hartung D, Bratberg J. Pharmacy staff-reported adaptations to naloxone provision and over the counter (OTC) syringe sales during the COVID-19 pandemic: experiences across multiple states and two pharmacy chains. Journal of the American Pharmacists Association 2024;64(1):71-78.

Hernandez I, Gabriel N, Kaltenboeck A, Boccuti C, Hansen RN, Sullivan SD. Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors. JAMA 2023;330(24):2390-92.

Tabah A, Gold LS, Marcum ZA, Hansen RN. Antidepressants and the Risk of Fall-related Injury in Older Adults with Incident Depression in the United States: A Comparative Safety Analysis. Pharmacoepidemiology 2023. In Press.

Bacci, JL, Marcum ZA, Rodriguez P, Hansen RN, Bansal A, Pfund T, Kim JJ, Odegard P. Community pharmacist intervention to optimize statin adherence in diabetes care: The GuIDE-S study. Journal of the American Pharmacists Association 2023;63(3):946-51.

Jiao B, Fredricks DN, Srinivasan S, Hansen RN. Economic Evaluation of a Point-of-Care Test for Bacterial Vaginosis among Women with Vaginal Symptoms. Sexually Transmitted Diseases 2023;50(5):310-6.

Jiang S, Seslar SP, Sloan LA, Hansen RN. Healthcare Resource Utilization and Costs Associated with Atrial Fibrillation and Rural-urban Disparities. Journal of Managed Care and Specialty Pharmacy 2022;28(11):1321-30.

Nitkin D, Lin GA, Campbell JC, Hansen RN, Brouwer E, Chen Y, Herron-Smith S, Agboola F, Pearson SD. The Effectiveness and Value of Tirzepatide for Type 2 Diabetes Mellitus. Journal of Managed Care and Specialty Pharmacy 2022;28(6):680-4.

Ko GC, Hansen RN, Carlson JJ. Comparing Costs and Healthcare Resource Utilization Between nmHSPC and mHSPC Patients: A Retrospective Claims Analysis. Journal of Managed Care and Specialty Pharmacy 2022;28(3):287-95.

Agboola F, Atlas SJ, Brouwer E, Carlson JJ, Hansen RN, Herron-Smith S, Nhan E, Rind DM, Pearson SD. JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Effectiveness and Value. Journal of Managed Care and Specialty Pharmacy 2022;28(1):108-14.

Bratburg J, Irwin A, Hartung D, Floyd A, Bogis J, Hansen RN, Green T. Study Protocol for the Respond to Prevent Study: A multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies. Substance Abuse 2022;41(3):901-5.

Hansen RN, Saour B, Serafini B, Hannaford B, Kim L, Kohno T, James R, Monsky W, Seslar S. Opportunities and Barriers to Rural Telerobotic Surgical Healthcare in 2021: Report and Research Agenda from a Stakeholder Workshop. Telemedicine and e-Health 2022;28(7):1050-7.

Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. ‘Treat my whole person, not just my condition’: Qualitative explorations of Hepatitis C care delivery preferences among people who inject drugs. Addiction Science and Clinical Practice 2021;16 (1):52.

Pocobelli G, Akosile MA, Hansen RN, Eavey J, Wellman RD, Johnson RL, Carls G, Bron M, Dublin S. Obstructive Sleep Apnea and Risk of Motor Vehicle Accident. Sleep Medicine 2021;85:196-203.

Banta-Green CJ, Hansen RN, Ossiander EM, Wasserman CR, Merrill JO. Buprenorphine utilization among all Washington State residents based upon prescription monitoring program data- Characteristics associated with two measures of retention and patterns of care over time. Journal of Substance Abuse Treatment 2021;127:108446 epub.

Brouwer E, Yeung K, Barthold D, Hansen RN. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in one mid-size integrated health system. Journal of Managed Care and Specialty Pharmacy 2021;27(6):732-42.

Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN. Cost-Effectiveness of Oral Semaglutide Added to Current Antihyperglycemic Treatment for Type 2 Diabetes. Journal of Managed Care and Specialty Pharmacy 2021;27(4):455-68.

Landaas EJ, Baird GS, Hansen RN, Flum DR, Sullivan SD. Integrating Formal Technology Assessment into an Integrated Healthcare Delivery System: Smart Innovation. International Journal of Health Technology Assessment in Health Care 2020;36(1):58-63.

Tice JA, Guzauskas GF, Hansen RN, Herron-Smith S, Segel C, Walsh JME, Pearson SD. The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy. Journal of Managed Care and Specialty Pharmacy 2020;26(5):620-3.

Gold LS, Nazareth TA, Yu T, Fry KR, Mahler N, Rava A, Waltrip RW, Hansen RN. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms. Pediatric Health, Medicine and Therapeutics 2019;10:195-207.

Gold LS, Patrick DL, Hansen RN, Goss CH, Kessler L. Correspondence between Lung Function and Symptom Measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Journal of Cystic Fibrosis 2019;18(6):886-93.

Bacci JL, Hansen RN, Ree C, Reynolds MJ, Stergachis A, Odegard PS. The effects of vaccination forecasts and value-based payment on adult immunizations by community pharmacists. Vaccine 2019;37(1):152-9.

Shelly Gray

Education

  • PharmD, University of Michigan
  • MS in Epidemiology, University of Washington

Courses Taught

  • PHARM 562: Pharmacotherapeutics V
  • PHARM 550: Seminar in Geriatrics

Research Interests

  • Medication safety in older adults
  • Deprescribing
  • Medication use and risk for falls, fractures, dementia

Biography

Dr. Gray has been a faculty member in the UW Department of Pharmacy since 1992. She is an investigator on numerous federally funded research grants and is author of more than sixty peer-reviewed publications. Earlier in her career, she received an American Association of Colleges of Pharmacy New Investigator Award and a Career Development Award from the National Institute on Aging. She serves on the editorial board for the “Annals of Pharmacotherapy”, “Journal of the American Geriatrics Society” and “Research in Gerontological Nursing”.

Gray has served as a consultant pharmacist for Providence Elderplace. Previously, she completed a two-year fellowship in geriatrics at the University of North Carolina at Chapel Hill and a clinical pharmacy residency at Thomas Jefferson University Hospital in Philadelphia. She has served on various committees of pharmacy and geriatric professional organizations.

Selected Publications

  • Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015:2175(3):401-7.
  • Gray SL, Dublin S, Yu O, Walker R, Anderson M, Crane P, Larson E. Benzodiazepine use and risk of incident dementia or cognitive decline. BMJ. 2016;352:i90.
  • Gray SL, Walker RL, Dublin S, Yu O, Bowles EJ, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk. J Am Geriatr Soc. 2018;66(2):247-253.
  • Gray SL, Anderson ML, Hanlon JT, Dublin S, Walker R, Hubbard, RA, Yu O, Montine T, Sonnen J, Keene CD, Crane PK, Larson EB. Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy cohort. J Alzheimers Dis 2018;65(2):607-616.

Louis Garrison

Education

  • PhD in Economics, Stanford University
  • Bachelor of Arts in Economics, Indiana University

Research Interests

  • National and international health policy issues
  • Economic evaluation of pharmaceuticals, devices, diagnostics, and other technologies
  • Personalized/precision/regenerative medicines

Courses taught

  • PHARM 534/HSERV 583: Economic Evaluation in Health and Medicine
  • PHARM 568: Health Economics
  • PHARM 581: Global Health Pharmacy
  • PHARM 582C: Global Health Pharmacy-Pharmacoeconomics
  • PHARM 532: Pharmaceutical Policy

Biography

Dr. Lou Garrison is Professor Emeritus in The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute in the School of Pharmacy, where he joined the faculty in 2004.  In October 2016, he became Senior Visiting Fellow at the Office of Health Economics, London, UK.  For the first 13 years of his career, Dr. Garrison worked in non-profit health policy research first at the Battelle Human Affairs Research Centers (Seattle), and then at the Project HOPE Center for Health Affairs (Virginia), where he was the Director from 1989-1992.  Following this, he worked as an economist in the pharmaceutical industry for 12 years. From 2002-2004, he was Vice President and Head of Health Economics & Strategic Pricing in Roche Pharmaceuticals, based in Basel, Switzerland.

Dr. Garrison received a BA in Economics from Indiana University, and a PhD in Economics from Stanford University. He has more than 150 publications in peer-reviewed journals.

Dr. Garrison was elected as ISPOR President for July 2016-June 2017.  He served on the ISPOR Board of Directors from 2007-09 as well as from 2015-8.  He co-chaired two ISPOR Good Practice Task Forces—on Real-World Data and on Performance-Based Risk-Sharing Arrangements—and he chaired the ISPOR Health Science Policy Council from 2012 to 2015.  He also recently co-chaired the ISPOR Special Task Force on U.S Value Frameworks, and he is faculty advisor for the UW ISPOR Student Chapter.  He is immediate past chair of the Past Presidents’ Council and the ISPOR Nominations Committee.  He was selected in 2017 by PharmaVOICE as being among “100 of the Most Inspiring People” in the industry.  He recently received the PhRMA Foundation and Personalized Medicine Coalition 2018 Value Assessment Challenge First-Prize Award as lead author on a paper on “A Strategy to Support the Efficient Development and Use of Innovations in Personalized and Precision Medicine.”

Webinars, videos, and podcasts

Selected Publications

  • Garrison LP, Jackson T, Paul D, Kenston M.  Value-based pricing for emerging gene therapies : the economic case for a higher cost-effectiveness threshold.  Journal of Managed Care & Specialty Pharmacy, Forthcoming e-publication. February 2019.
  • Garrison LP Jr, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value Health. 2018 Feb; 21(2):161-165.
  • Garrison LP Jr, Pauly MV, Willke RJ, Neumann PJ. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]. Value Health. 2018 Feb; 21(2):124-130..
  • Garrison LP, Kamal-Bahl, S, Towse, A.  Toward a Broader Concept of Value:  Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in Health 20 (2017)
  • Garrison LP Jr, Carlson JJ, Bajaj PS, Towse A, Neumann PJ, Sullivan SD, Westrich K, Dubois RW. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care. 2015 Sep;21(9):632-40.
  • Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):735-41
  • Towse A, Garrison LP Jr. Economic incentives for evidence generation:  promoting an efficient path to personalized medicine. Value Health. 2013 Sep-Oct;16(6 Suppl):S39-43
  • Garrison LP, Jr. (co-chair); Towse A (co-chair) et al.  Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force, Value in Health, August, 2013
  • Garrison LP and Veenstra DL.  The Economic Value of Innovative Treatments over the Product Life Cycle:  the Case of Targeted Trastuzumab Chemotherapy for Breast Cancer. Value in Health. 12(8): 1118-23, 2009
  • Garrison LP, Towse A, Bresnahan B.  Assessing a Structured, Quantitative Health Outcomes Approach  to Drug Risk-Benefit Analysis, Health Affairs, 26(3):684-95, 2007.
  • Garrison LP and Neumann PJ (co-chairs); Erickson P, Marshall D, Mullins CD.  Using real world data for coverage and payment decisions:  the ISPOR real world data task force report.  Value in Health 10(5):  326-335. September, 2007.
  • Garrison LP and Austin MJF.  The economics of personalized medicine:  a model of incentives for value creation and capture. Drug Information Journal 41: 501-509, 2007

Rachel Firebaugh

Education

  • PharmD, Pacific University
  • Master of Public Health, University of Montana
  • Bachelor of Arts in Psychology, University of Washington

Jennie Do

Education

  • PharmD, University of Washington

Research Interests

  • Institutional Pharmacy Practice
  • Interprofessional Education and Practice

Courses Taught

  • PHRMCY 541-542-543: Pharmacist Provider Readiness I, II, III
  • PHRMPR 531: Pharmacist Provider Experience I

Biography

Jennie Do is a Clinical Assistant Professor at the University of Washington School of Pharmacy. She received her Pharm.D. degree from the University of Washington, completed a Pharmacy Practice Residency, and is board certified in pharmacotherapy. Her practice experience includes several pharmacy settings: inpatient, long-term acute care, community, anticoagulation clinic, and home infusion.

 

Beth Devine

Education

  • MSc, Medical Statistics and Health Data Science, University of Bristol
  • Post-doctoral Fellowship, The CHOICE Institute, UW and Roche Global Pharma Business
  • PhD, Health Services Research, UW
  • MBA, University of San Francisco
  • PharmD, University of the Pacific
  • Clinical Pharmacy Residency, Palo Alto VA Medical Center

Research Interests

  • Evidence synthesis; systematic reviews, meta-analysis, network meta-analysis using Bayesian and frequentist methods.
  • Precision medicine: pharmacogenomics; genomic risk for hereditary cancers.
  • Health technology assessment and outcomes research including preference-based methods, discrete choice experiments and multi-criteria decision analysis.
  • Comparative effectiveness research in the context of clinical informatics.
  • Real world evidence of costs and outcomes.
  • Medication safety.

Biography

Beth Devine is Professor Emerita at The CHOICE Institute, School of Pharmacy Prior to becoming emerita, she held adjunct professorships in the Department of Health-Systems and Population Health, School of Public Health and the Department of Biomedical Informatics, School of Medicine.

She also held the Shirley and Herb Bridge Endowed Professor for Women in Pharmacy (2021-2023). She is currently a Visiting Professor at the University of Bristol, UK (2024-2026). She was a Fulbright US Scholar to the University of Murcia, Spain (2021-2022) and an Honorary Professor there (2022-2023).

She is currently president-elect of ISPOR – The Professional Society for Health Economics and Outcomes Research (2025-2026), was a member of the Board of Directors of ISPOR (2021-2024) and is an Associate Editor for the ISPOR journal Value in Health (2021-2029). She served on the ISPOR Task Force that developed guidelines to conduct network meta-analyses (2009-2011) and is currently co-chairing the ISPOR Task Force to update to these guidelines (2026). From 2014-2025 she served as an Assistant Director of the AHRQ-funded Pacific Northwest Evidence-based Practice Center. In 2013, she was elected as a member of the Society for Research Synthesis Methodology.

Prior to joining the faculty at the UW, Dr. Devine was an advanced practice (prescribing) clinical pharmacist and led the Pharmacy & Therapeutics Committee at the University of California San Francisco. where she served a term as president of the California Society of Health-System Pharmacists, earning their Lifetime Achievement Award for her leadership role in advancing the scope of practice for California pharmacists through legislation (1994).

Courses Taught

  • HEOR DS 510: Data Science in Health Economics and Outcomes Research
  • HECON 530 – Health Technology Assessment in a Global Environment
  • HEOR 531/HSERV 584 – Assessing Outcomes in Health & Medicine
  • PHRMCY 514 – Design and Analysis of Medical Studies

Selected Peer-Reviewed Publications

MyNCBI Bibliography
https://www.ncbi.nlm.nih.gov/myncbi/emily.devine.1/bibliography/public/

Google Scholar Profile: (n = 336; citations: 11294; h-index = 43, i10-index = 128)
https://scholar.google.com/citations?user=Wor4Qv0AAAAJ&hl=en

Karan Dawson

Education

  • PhD in Communication, University of Washington
  • Master of Science in Pharmacy (Minor in Business Administration), University of Washington
  • Bachelor of Science in Pharmacy, University of Washington

Research Interests

  • Education and professional development
  • Human behavior and communication
  • Geriatrics

Courses Taught

  • Pharm 584, 585, 586: Pharmacy Practice I, II and III
  • Pharm 532, PharmP 533: IPPE Hospital II and III

Biography

Following an internship at Valley Medical Center, Dr. Dawson worked as a clinical pharmacist at the Veterans Affairs (VA) Medical Center in Seattle, where she also completed a residency. She returned to the UW for an MS in Pharmacy to explore teaching and research, which led to becoming the director of continuing pharmacy education.

Dr. Dawson continued to pursue her interests in chronic diseases and substance abuse, areas of specialty developed during work at the VA. She was course master for the clinical therapeutics courses in both the School of Pharmacy and UW School of Nursing; managed the UW School of Pharmacy institutional clerkship program; and developed a number of electives including a first in tobacco cessation for teens run by pharmacy students and a self-care course for non-majors, which was aired on the UW educational television channel and included a live call-in show.

Given the changing needs of pharmacists to provide patient-centered care, she returned to the UW for a PhD in speech communication. She currently teaches in three pharmacy practice courses – a course for non-majors about medications and health; and a course in mind/body/medicine for graduate students in the health sciences.

She is one of three consulting pharmacists in an innovative, non-dispensing practice that serves retirement communities. She has won three awards for innovative teaching, served in a series of elective offices for the American Association of Colleges of Pharmacy, and continues to precept pharmacy clerkship students. Her current research interests are in the areas of teaching effectiveness, the provision of non-dispensing pharmacy services, and application of mind/body/spirit/medicine techniques to enhance professional self-care and patient well-being.

Lingtak-Neander Chan

Education

  • BS in Pharmacy (Northeastern University)
  • BS in Toxicology (Northeastern University)
  • PharmD (University of Washington)
  • Board-Certified Nutrition Support Pharmacist

Courses Taught

  • PHARM 510
  • PHARM 557
  • PHARM 569
  • PHARM 571
  • PHARM 562
  • PHRMCY 535
  • PHRMCY 537

Research

  • FocusClinical Nutrition
  • Micronutrient deficiencies and treatments
  • Nutritional anemia
  • Nutrition support in critically ill patients
  • Pharmaco- and nutrient kinetics after bariatric surgery or bowel resection

Biography

Lingtak-Neander Chan is a Professor of Pharmacy in the School of Pharmacy, and an Interdisciplinary Faculty of the Graduate Program in Nutritional Sciences at the University of Washington, Seattle. He was formerly a faculty member of the College of Pharmacy and College of Medicine at the University of Illinois at Chicago. He is a board-certified nutrition support pharmacist, an elected fellow of the American College of Nutrition and an elected fellow of the American College of Clinical Pharmacy.

His primary research focus is on the absorption kinetics of micronutrients and drugs after bariatric surgery and other GI tract repairs. Other key areas of interest include micronutrient deficiencies, intestinal failure, critical care nutrition.

Dr. Chan is the 43rd president of the American Society for Parenteral and Enteral Nutrition (ASPEN) in 2019-2020

Selected Publications

  • Chan LN. Cardiovascular Risk Reduction with Icosapent Ethyl. N Engl J Med. 2019 Apr 25;380(17):1677.
  • Blaauw R, Osland E, Sriram K, Ali A, Allard JP, Ball P, Chan LN, Jurewitsch B, Logan Coughlin K, Manzanares W, Menéndez AM, Mutiara R, Rosenfeld R, Sioson M, Visser J, Berger MM. Parenteral Provision of Micronutrients to Adult Patients: An
    Expert Consensus Paper. JPEN J Parenter Enteral Nutr. 2019 Mar;43 Suppl 1:S5-S23.
  • Dickerson RN, Kumpf VJ, Bingham AL, Blackmer AB, Canada TW, Chan LN, Cogle SV, Tucker AM. Significant Published Articles for Pharmacy Nutrition Support Practice in 2017. Hosp Pharm. 2018 Jul;53(4):239-246.
  • Worthington P, Balint J, Bechtold M, Bingham A, Chan LN, Durfee S, Jevenn AK, Malone A, Mascarenhas M, Robinson DT, Holcombe B. When Is Parenteral Nutrition Appropriate? JPEN J Parenter Enteral Nutr. 2017 Mar;41(3):324-377.
  • Chan LN, Neilson CH, Kirk EA, Colovos TF, Javelli DR, Khandelwal S. Optimization of Vitamin D Status After Roux-en-Y Gastric Bypass Surgery in Obese Patients Living in Northern Climate. Obes Surg. 2015 Dec;25(12):2321-7.
  • Chan LN, Lin YS, Tay-Sontheimer JC, Trawick D, Oelschlager BK, Flum DR, Patton KK, Shen DD, Horn JR. Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates. Pharmacotherapy. 2015 Apr;35(4):361-9.
  • Chan LN, Seres DS, Malone A, Holcombe B, Guenter P, Plogsted S, Teitelbaum DH. Hangover and hydration therapy in the time of intravenous drug shortages: an ethical dilemma and a safety concern. JPEN J Parenter Enteral Nutr. 2014
    Nov;38(8):921-3.
  • Chan LN, Mike LA. The science and practice of micronutrient supplementations in nutritional anemia: an evidence-based review. JPEN J Parenter Enteral Nutr. 2014 Aug;38(6):656-72.
  • Chan LN. Warfarin dosing changes after bariatric surgery: implications on the mechanism for altered dose requirements and safety concerns–an alternative viewpoint. Pharmacotherapy. 2014;34(4):e26-8.
  • Chan LN. Drug-nutrient interactions. JPEN J Parenter Enteral Nutr. 2013
    Jul;37(4):450-9.
  • Mornar S, Chan LN, Mistretta S, Neustadt A, Martins S, Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol. 2012 Aug;207(2):110.e1-6.
  • American College of Clinical Pharmacy, Boyce EG, Burkiewicz JS, Haase MR, MacLaughlin EJ, Segal AR, Chung EP, Chan LN, Rospond RM, Barone JA, Durst SW, Wells BG. ACCP position statement: Clinical faculty development. Pharmacotherapy.
    2009 Jan;29(1):124-6.
  • Pai AB, Norenberg J, Boyd A, Raj D, Chan LN. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study. Clin Ther. 2007 Dec;29(12):2699-705.
  • Haugen HA, Chan LN, Li F. Indirect calorimetry: a practical guide for clinicians. Nutr Clin Pract. 2007 Aug;22(4):377-88.

Anirban Basu

Education

  • PhD, Public Policy (Health Economics), University of Chicago, 2004
  • MS, Biostatistics, UNC-Chapel Hill, 1999
  • MS, Industrial Pharmacy, University of Toledo, 1997
  • BS, Pharmaceutical Technology, Jadavpur University India

Courses Taught

  • Welfare Economics foundations for cost-effectiveness analysis (HSERV 583, ’11 & ‘12) – 1.5 hour sessions
  • Understanding the role of uncertainty in decision models (HSERV 583, ’13 & ‘14) – 1.5 hour sessions
  • Quantitative methods for valuing information in health care (HSERV 584, ‘11) – 1.5 hour sessions
  • Introduction to comparative effectiveness methods (HSERV 523, ’11; HSERV 513 & HSERV 592, ’12) – 1.5 hour sessions
  • Instrumental variable methods (HSERV 523, ‘11) – 1.5 hour session
  • Financing healthcare (HuBio 555, ’13, ‘14) – 1.5 hour session to 250 2nd year medical students
  • Quantile regression methods (HSERV 525, ’11, HSERV 523, ‘12) – 1.5 hour sessions
  • Variations in healthcare spending: Observations & Implications (PHARM 568, ’14 -‘16) – 1.5 hour sessions
  • Causal inference in observational studies (HSERV 525), Spring 2013 -2019- Ten 3 hour sessions.

Research Interests

  • comparative and cost-effectiveness analyses
  • causal inference methods
  • program evaluation, and outcomes research

Biography

Anirban Basu, PhD, MS, is a health economist and a statistician who specializes in research on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research. He directs The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington, Seattle, with appointments in the departments of Pharmacy, Health Services, and Economics at the university. He is a Faculty Research Fellow at the National Bureau of Economic Research, and a Fellow of the American Statistical Association. He was one of the panelists for the Second Panel on the Cost-Effectiveness Analysis in Health and Medicine. He studies heterogeneity in clinical and economic outcomes, micro behavior with respect to heterogeneous information, and the value of individualized care. He teaches topics in health economics, decision analysis, cost-effectiveness analysis, and health services research methods. He received his PhD in Public Policy (Health Economics Specialization) from The University of Chicago and an MS in Biostatistics from the University of North Carolina at Chapel Hill. http://faculty.washington.edu/basua/

Selected Publications

https://scholar.google.com/citations?user=AR72duAAAAAJ&hl=en

Jennifer Bacci

Education:

  • PharmD, University of Pittsburgh School of Pharmacy
  • MPH, University of Pittsburgh School of Public Health

Research Interests:

  • Community-based pharmacy practice
  • Implementation science
  • Prevention and public health

Courses Taught: 

  • PHRMCY 501: Foundations of Being a Pharmacist I
  • PHRMCY 502: Foundations of Being a Pharmacist II
  • PHARM 523: Insights into Community Pharmacy Practice Transformation

Biography: 

Dr. Bacci is the Endowed Associate Professor of Innovative Pharmacy Practice at the University of Washington School of Pharmacy. Her research focuses on the application of implementation science to evaluate and advance the adoption of innovative patient care models in community pharmacy practice, including childhood and adult vaccinations, point-of-care testing, chronic disease management, pharmacist prescribing, and medical billing. Dr. Bacci collaborates closely with community partners to address needs and challenges faced by practitioners and patients and amplify the positive impact of community-based pharmacy teams.

Dr. Bacci practiced in community pharmacy for 10 years in chain and independent settings and is a Board Certified Ambulatory Care Pharmacist (BCACP). She remains highly engaged in practice as a member of the Washington State Pharmacy Association (WSPA) Board of Directors, a Network Facilitator for CPESN WA, a clinically integrated network of independent pharmacies in Washington State, and as a leader in the Academia-Community Transformation (ACT) Pharmacy Collaborative, a nationwide collaboration to support and facilitate community pharmacy practice transformation efforts.

Dr. Bacci has been honored with the 2021 Albert B. Prescott Pharmacy Leadership Award and 2019 Washington State Distinguished Young Pharmacist of the Year Award. Dr. Bacci and her research collaborators have been recognized with the 2018 NAIIS “Immunization Neighborhood” Adult Immunization Champion Award and 2018 American Pharmacist Association Immunization Champion Award.

Dr. Bacci completed her PharmD at PittPharmacy in 2011 followed by followed by a PGY-1 Community-based Pharmacy Residency with PittPharmacy and Rite Aid. After working full-time in community practice, she returned to PittPharmacy to complete a two-year Community Pharmacy Research Fellowship.

Selected Publications:

Wittenauer R, Shah PD, Bacci JL, Stergachis A. Locations and characteristics of pharmacy deserts in the United States: a geospatial study. Health Aff Sch. 2024;2(4):qxae035. Published 2024 Mar 16. doi:10.1093/haschl/qxae035

Bacci JL, English C, Odegard PS, Stergachis A, Snyder CR, Danielson JH. A 2023 Washington State pharmacist workforce survey: Employment and patient care roles. J Am Pharm Assoc (2003). 2025;65(1):102314. doi:10.1016/j.japh.2024.102314

Bacci JL, Nwogu IB, Zaraa S, et al. A community pharmacist intervention for people living with epilepsy. J Am Pharm Assoc (2003). 2025;65(1):102275. doi:10.1016/j.japh.2024.102275

Bhardwaj S, Galanter N, Berenbrok LA, Shah PD, Bacci JL. Pediatric vaccination in pharmacies is not associated with delayed well-child visits among commercially insured children. Health Aff Sch. 2025;3(2):qxaf028. Published 2025 Feb 10. doi:10.1093/haschl/qxaf028

Bacci JL, Marcum ZA, Rodriguez P, et al. Community pharmacist intervention to optimize statin adherence in diabetes care: The GuIDE-S study. J Am Pharm Assoc. 2023;63(3):946-951. doi:10.1016/j.japh.2023.03.002

Bacci JL, Rodriguez T, Hansen R, et al. Community pharmacist intervention to close statin gaps in diabetes care: The GuIDE-S study. J Am Pharm Assoc. 2023;63(1):108-117. doi:10.1016/j.japh.2022.08.025

Bacci JL, Coley K, Daly C, et al. Qualitative analysis of community pharmacy practice transformation. J Am Coll Clin Pharm. 2022; 5(12):1236-1252. doi:10.1002/jac5.1728

Bacci JL, Odegard P, Arnold J, Stergachis A. Strengthening pandemic preparedness through pharmacy and public health collaborations: Findings from a facilitated discussion exercise. J Am Pharm Assoc. 2021;61(3):e99-e106. doi:10.1016/j.japh.2020.12.024

Bacci JL, Zaraa S, Stergachis A, Simic G, White HS. Community pharmacists’ role in caring for people living with epilepsy: A scoping review. Epilepsy Behav. 2021;117:107850. doi:10.1016/j.yebeh.2021.107850

Bacci JL, Hansen R, Ree C, Reynolds MJ, Stergachis A, Odegard PS. The effects of vaccination forecasts and value-based payment on adult immunizations by community pharmacists. Vaccine. 2019;37(1):152-159. doi:10.1016/j.vaccine.2018.11.018

Wang AB, Bacci JL, Amoo M, Ree C, Firebaugh R, Odegard P. Impact of an immunization platform in community pharmacies. J Am Pharm Assoc. 2019;59(4S):S151-S155. doi:10.1016/j.japh.2019.05.007

Akers JL, Meer G, Kintner J, Shields A, Dillon-Sumner L, Bacci JL. Implementing a pharmacist-led in-home medication coaching service via community-based partnerships. J Am Pharm Assoc. 2019;59(2):243-251. doi:10.1016/j.japh.2018.11.008

 

 

Rachel Allen

Education

  • Doctor of Pharmacy – University of Washington

Courses Taught

  • PHARM 584, 585, 586: Pharmacy Practice I, II, III
  • PHARM 521: Pharmacy Teaching Practicum
  • PHARMP 511, 512, & 513: Introductory Pharmacy Practice Experience in Community Pharmacy I, II, III

Research Interests

  • Scholarship of teaching and learning in the areas of skill development and experiential education, with a particular passion for assessment.

Biography

Rachel Allen received her PharmD degree from the University of Washington where she received the UW Foster School of Business Certificate in Pharmacy Management.  She was the first PGY1 resident at Bartell Drugs/University of Washington.  She transitioned into the Clinical Care Coordinator role at Bartell Drugs for 5 years, where she focused on the provision and management of clinical services such as immunizations, MTM, and disease state management.  She became interested in teaching during her residency and pursued her interest in academia by helping to instruct and coordinate the PY1 Pharmacy Practice Course series since 2009.  Currently, Rachel is an Associate Teaching Professor at the UW School of Pharmacy, where she is a co-course master for the PY1 Pharmacy Practice Course series, Director for the Community Introductory Pharmacy Practice Experience (IPPE) Program, and Assistant Dean for Professional Affairs and Practice.  She is looking forward to the new curriculum and being a course master for Wednesdays in Practice. Her areas of interest include communication skill development and scholarship of teaching and learning in the areas of skill development and experiential education, with a particular passion for assessment.  Rachel enjoys mentoring students who are educational assistants involved in skills lab teaching and via precepting outreach events. Outside of pharmacy, Rachel is a self-proclaimed foodie and enjoys traveling and spending time with her husband Shawn, son Grayson, and daughter Ava.

Selected Publications

  • Panther SG, Allen RA, Brantner K, Jefferson CJ, Murphy NL, Robinson JD. Addressing unmet patient care needs through curricular development of student pharmacist leadership and entrepreneurial skills. (2019) American Journal of Pharmaceutical Education. https://doi.org/10.5688/ajpe6764
  • Bellottie GD, Kirwin J, Allen RA, Anksorus HN, Bartelme KM, Bottenberg MM, Dula CC, Kane TH, Lee PH, McMillan A, Riley BL, Waghel R. Suggested pharmacy practice laboratory activities to align with pre-APPE domains in the Doctor of Pharmacy curriculum. (2018) Currents in Pharmacy Teaching and Learning. https://doi.org/10.1016/j.cptl.2018.06.001

Jennifer Chang

Education

  • Bachelor of Science in Pharmaceutical Sciences, University of British Columbia.
  • Doctor of Pharmacy, University of Minnesota.
  • PGY-1 Pharmacy Practice Residency, UW Medicine
  • Board Certified Pharmacotherapy Specialist (BCPS)

Research Interests

  • Patient safety and quality improvement
  • Pharmacy Education (Scholarship of Teaching and Learning)
  • Experiential Education

Courses Taught

  • PHRMCY 513: Applied Patient Safety and Quality
  • PHRMCY 541-542-543: Pharmacist Provider Readiness I, II, III
  • PHRMPR 511-512-513: Pharmacist Provider Experience I, II, III
  • PHRMPR 541: Introductory Pharmacy Practice Experience in Institutional Health-System
  • PHARM 594: Pharmacy Practice VI Medication Safety and Quality
  • PHARM 593: Pharmacy Practice V Institutional Practice

Biography

Dr. Jennifer Chang is an Associate Teaching Professor at the University of Washington (UW) School of Pharmacy. Her professional interests include patient safety and quality, institutional practice, and scholarship of teaching and learning in the areas of skill development and experiential education. She provided leadership and oversight in the design and implementation of the new Pharmacist Provider Series (PPS) in the PharmD curriculum. Dr. Chang collaborates closely with practice experts and faculty to design and coordinate student learning experiences on- and off-campus to ensure student readiness for practice. Dr. Chang earned her Bachelor of Science in Pharmaceutical Sciences degree from the University of British Columbia in 1995 and her Post-Baccalaureate Doctor of Pharmacy degree from the University of Minnesota in 1997. She completed her PGY-1 residency training at the University of Washington in 1998 and is a Board Certified Pharmacotherapy Specialist (BCPS). Dr. Chang has held a variety of positions in the health systems setting, including roles in clinical practice, pharmacy administration, medication safety, and pharmacist education. Dr. Chang currently teaches in the PY1 PPS course series with the PY1 PPS faculty team and serves as a co-course master for the Applied Patient Safety and Quality course. She also serves as a Co-Director for the UW School of Pharmacy Teaching and Learning Certificate Program. She enjoys precepting and mentoring students as well as PGY1 residents. Dr. Chang and the PY1 PPS Team have been honored with the 2023 UW Distinguished Teaching Award for Teams and the 2021 UW School of Pharmacy First Professional Year Excellence in Teaching Award.

Josh Carlson

Education

  • PhD in Public Health Genetics, University of Washington
  • Master of Public Health in Public Health Genetics, University of Washington

Research Interests

  • Economic Evaluation of Healthcare Interventions
  • Comparative Effectiveness Research
  • Precision Medicine

Courses Taught

  • HEOR 530
  • PHRMCY 515

Biography

Dr. Carlson is a Professor in the The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute in the School of Pharmacy at the University of Washington. He graduated with his PhD from the Institute for Public Health Genetics in the School of Public Health and Community Medicine at the University of Washington in 2007 and conducted his postdoctoral training in health economics and outcomes research in the Pharmaceutical Outcomes Research and Policy Program (now the CHOICE Institute) at the University of Washington from 2007-2009. He was awarded the ISPOR Bernie J. O’Brien new investigator award in 2014.

Dr. Carlson’s research seeks to inform healthcare decision making using economic modeling, evidence synthesis, preference assessment, and health policy evaluation. This work spans many diseases, topics, and methodologies, but specific focus areas include economic analysis, precision medicine, and performance-based risk sharing arrangements. He has diverse formal training in decision modeling, discrete choice experiments, comparative effectiveness, outcomes research, and public health genetics.

Douglas Black

Education

  • Doctor of Pharmacy (UW, 1983)

Research Interests

  • Antibiotic resistance
  • Infectious disease pharmacotherapy
  • Drug interactions

Biography

Douglas Black is Professor Emeritus at the University of Washington School of Pharmacy. He earned his Doctor of Pharmacy from the UW in 1983. During 1983-1989 he served as oncology pharmacist for the UW Medical Center, participating in the design, completion, and analysis of two febrile neutropenia antibiotic trials. Doug has provided pharmacy consultation to the UW General Infectious Disease service for almost 30 years, instructing hundreds of pharmacy students and residents on the pharmacokinetics and pharmacodynamics of antimicrobial agents and collaborating with infectious disease physicians on multiple projects involving antibiotic resistance and the pharmacokinetics of drug interactions. Doug has served as contributing editor in pharmacology for The Sanford Guide to Antimicrobial Therapy since 2010.

Selected Publications

  • Baradaran S, Black DJ, Keyloun KR, Hansen RN, Gillard PJ, Devine EB. The impact of acute kidney injury on the risk of mortality and healthcare utilization among patients treated with polymyxins for severe gram negative infections. Open Forum Infect Dis 5(8):ofy191, 2018.
  • Chow S-K, Jain R, Black D, Pottinger PS, Fang FC, Butler-Wu SM. The devil is in the details: impact of penicillin susceptibility reporting on the treatment of streptococcal infective endocarditis. Clin Infect Dis 2016; 62: 264-5.
  • Bauer LA, Black DJ, Lill JS, Garrison J, Raisys VA, Hooton TM. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrob Agents Chemother 49 (4): 1649-51, 2005.
  • Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621-625.
  • Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole II: a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-428.

Alvin Goo

Education

  • Bachelor of Science, Pharmacy (UW 1992)
  • Doctor of Pharmacy (UW 1994)

Research Interests

  • Primary Care

Courses Taught

  • PHRMCY Provider Ready 544, 545, 546
  • PHRMPR Provider Experience 514, 515, 516
  • PHARM 598 Seminar in Pharmacy Practice Topics

Biography

Alvin Goo is a Clinical Associate Professor at the University of Washington School of Pharmacy and School of Family Medicine. He received his Doctor of Pharmacy and PGY1 residency from the UW in 1994 and completed a PGY2 residency at MUSC in 1995. Alvin practices in a collaborative interdisciplinary primary care clinic since 1995 and currently at the HMC Family Medicine clinic. Alvin is also the Pharmacy PGY2 Ambulatory Care Residency Director, and involved with training pharmacy students, residents, and Family Medicine residents.